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SUMMARY 
 II 
  II SUMMARY 
In the wider field of nutrition, intensive efforts are under way to determine 
the effects of various nutrients on growth and development. The object of the 
present study is to demonstrate the effects of different dietary levels of DHA and/ 
or GLA from different oils in the presence of constant amount of LCPs n-3 (EPA) 
and AA as LCPs n-6 on the fatty acid patterns of brain, liver, plasma and their 
phospholipids during experiment at two stage (the first one after four weeks and 
the second after eight weeks). Rates with omega 6 diets were present various 
metabolic fatty acids pathway, liver and plasma fatty acids were significantly 
related after four weeks. Liver DHA was positively correlated with plasma DHA (r 
= 0.81, P< 0.05) and liver AA was positively correlated with plasma AA (r = 0.86, 
P< 0.05). Plasma and liver AA were not correlated with brain and kidney AA. 
However, DHA in liver and plasma DHA were significantly associated with DHA 
in brain (r = 0.81 and 0.92, P< 0.05), respectively. Brain DHA had not related with 
the increase with DHA in diets. In all groups, there was trend for α-tocopherol to 
decrease with time, especially between 4 week and 8 weeks of feeding with 
significance difference between the low and high level of ω-3 as well as low ω-6 
and high concentration. The extracted liver and brain oils from low ω-3 as or ω-6 
fed rats had the strongest radical scavenging activity compared to high levels 
with positive correlation between RSA and the levels of tocopherols in detected 
oils. The storage test existed correlations between peroxide value (PV) and 
conjugated dienes (CD) (P< 0.05) as well as 2-thiobarbituric acid-reactive 
substances (TBARS) and headspace volatiles (hexanal and propanal) content 
(P< 0.001) for most oils and extracted oils. Besides, it was found that a negative 
correlation was demonstrated between the TBRAS formation and the total 
phenolic contents. We can conclude that, high levels of DHA not contribute to 
increase of DHA in brain, liver or plasma beside reduction of plasma AA by 
adding EPA+ DHA to the diet with different amounts of GLA may be important to 
use for infant fed formula with a family history of inflammatory condition such as 
rheumatoid arthritis or AD diseases.  
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Studien zur Stabilität und zur Verteilung von 
polyungesättigten Fettsäuren in Rattengewebe 
                       
Einleitung 
Muttermilch ist in ihrer Zusammensetzung ideal auf die biologischen 
Bedürfnisse des Babys abgestimmt. Das Fett der Muttermilch und der 
Nahrung sind der wichtigste Energieträger für den Säugling. Es liefert ca. 
40 - 55 % der zugeführten Energie. Die wichtigsten Bestandteile der 
Nahrungslipide (Triglyceride, Phospholipide und Cholesterinester), nämlich die 
langkettigen polyungesättigten Fettsäuren (LCPs) sind essenziell für das normale 
Wachstum und die Entwicklung des Säuglings (3, 4). Die beiden Gruppen der 
LCPs, die omega-3- (ω-3) und omega-6-Fettsäuren (ω-6) haben besonders 
wichtige Funktionen: Docosahexaensäure (DHA; C22:6n-3) in Netzhaut und 
Gehirn, und Arachidonsäure (AA; C20:4n-6) als Vorläufer der Eicosanoide, die 
bei einer ganzen Reihe zellulärer Prozesse wichtig sind. Muttermilch wird als 
beste Quelle für essentielle Fettsäuren betrachtet; neben anderen Fettsäuren 
enthält sie die essentielle Linolsäure (LA; C18:2n-6) und alpha-Linolensäure (α-
LA; C18:3n-3), und die LCPs: Arachidonsäure (AA) und Docosahexaensäure 
(DHA) (6-8).  
 
Die Untersuchungen zeigen, dass das Neugeborene im Stande ist AA aus 
LA und DHA aus alpha-LA zu synthetisieren. Jedoch ist der Betrag der LCPs, 
besonders der an DHA, der erzeugt werden kann, infolge einer verminderten 
Desaturasekapazität nicht ausreichend um den Entwicklungsanforderungen das 
Säuglings gerecht zu werden, was eine exogene Versorgung mit LCPs während 
der ersten Lebensmonate erfordert (6, 10). Der Bedarf von Neugeborenen an 
LCPs ist ein Forschungsschwerpunkt im letzten Jahrzehnt gewesen. Ein 
Grund ist die Beobachtung, dass bei zu früh Geborenen die 
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Blutplasmawerte an LCPs nach der Geburt in mit Frühchenmilch 
gefütterten Säuglingen deutlich abnehmen verglichen mit fast 
unveränderlichen Niveaus in mit Muttermilch genährten Frühchen (12).  
 
Diese Studie wurde mit Fütterungsversuchen an Ratten durchgeführt 
(Tabelle 1). Es wurden zwei Diätgruppen gebildet: eine omega-3-Gruppe 
mit DHA (1, 2, 3%) und eine omega-6-Gruppe mit GLA (1, 3, 5%). Ziel der 
Studie war es (a) die Wirkung der zunehmenden DHA-Menge auf die 
Fettsäurespektren in Gehirn, Leber und Blutplasma (Gesamt- und Phospholipide) 
innerhalb der ersten acht Wochen zu studieren; und (b) die Wirkung von 
diätetischer GLA in Gegenwart vom omega-3-Fettsäuren auf die 
Fettsäuremustern (Eicosanoid-Vorgänger) zu bewerten. Der Tocopherolgehalt 
(c) und die antioxidative Wirksamkeit (DPPH, d) in vivo wurde bestimmt. 
Ausgehend von den Ergebnissen beider Gruppen wurden drei 
verschiedene (Verhältnis %DHA zu %GLA; 1:1, 1:3, 3:0) pulverförmige 
Babynahrungspräparate hergestellt (Öl-Emulsion/AIG93 Diät-Trocknung-
Lagerung) und deren Lagerfähigkeit bei 60°C überprü ft. 
 
Zusammenfassung 
Die Gehalte von DHA (omega-3-Gruppe) in Plasma und Gehirn 
korrelieren nach vier Entwicklungswochen miteinander (r = 0.82, P <0.05), 
gleiches gilt für AA (r = 0.89, P <0.05). Nach acht Wochen ergeben sich im 
Gehirn vergleichbare DHA-Werte, unabhängig von der Fütterungsmenge 
(1-3%). In den omega-6-Fütterungsversuchen korrelieren Leber-DHA und 
Plasma-DHA (r = 0.81, P <0.05), als auch Leber- und Plasma-AA (r = 0.86, 
P <0.05). Leber- und Plasma-DHA korrelieren nach vier Wochen auch mit 
Gehirn (r = 0.81, P <0.05) ,dies gilt aber nicht für AA. Als Grund wird die 
Blockierung der ∆5-Desaturase durch die Konkurrenzreaktion EPA zu DHA 
angenommen (Figure 1). Zusammenfassend lässt sich sagen, dass die 
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Verhältnisse zwischen Nahrungsfetten und Körperfetten über den 
Fettstoffwechsel sehr komplex sind. Die über die Fütterung verursachte 
Verschiebung der Fettsäurezusammensetzung ist in der Leber am 
größten. Hier findet der Stoffwechsel statt und über das Blut gelangen die 
Fettsäuren ins Gehirn. Von dem DHA-Gehalt im Blutplasma kann man 
direkt auf den Gehalt in den Geweben schließen. Die zur Entwicklung des 
Gehirns, welche bei Ratten nach 28 Tagen beim Menschen nach dem 2. 
Lebensjahr abgeschlossen ist, notwendige DHA wird bereits mit 1% im 
Nahrungsfett ausreichend zugeführt. Die Verabreichung größerer Mengen 
führt zu keinem weiteren Anstieg im Gehirn.  
 
Im Gegensatz zu anderen Studien konnte gezeigt werden, dass die 
Gabe von GLA, AA, EPA und DHA zu einer Senkung der Plasma-AA und 
einer Steigerung der Gehirn-DHA führt. Diese Beobachtung könnte eine 
neue Therapiemöglichkeit für Menschen eröffnen, die an Beschwerden 
leiden, welche aus dem Arachidonsäure-Stoffwechsel (Eicosanoide) 
herrühren, z.B. Neurodermitis und Multiple Sklerose.     
 
Die untersuchten Proben enthalten α-Tocopherol und Spuren von γ-
Tocopherol. Innerhalb der ersten acht Entwicklungswochen nimmt die 
Tocopherolgehalt stark ab, der Effekt wird durch steigende LCPs-
Verabreichung, sowohl in der omega-3- als auch in der omega-6- Gruppe 
noch verstärkt (Tabelle 13). Dieses Ergebnis entspricht dem anderer 
Studien an Ratten bzw. Mäusen (99, 100) die zeigten, dass höhere 
Gehalte an omega-3-FA kleinere Tocopherolgehalte verursachen. 
Zwischen der gemessenen antioxidativen Wirksamkeit (RSA) und der 
Tocopherolkonzentration besteht ein direkter Zusammenhang.  
Die Lagerstabilität der drei pulverförmigen Babynahrungspräparate 
beträgt bei 60 °C unabhängig von der Formulierungsf orm (Öl/Pulver) etwa 
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sechs Tage, dies entspricht etwa drei Monaten bei 20 °C. Die 
unterschiedlichen Verhältnisse von DHA zu GLA haben keinen 
signifikanten Einfluss. PV, AV und CD korrelieren miteinander, ebenso 
TBARS und flüchtige Verbindungen. Die Aldehyde des Fettverderbs 
korrespondieren mit den anderen Verderbsparametern und steigen nach 
etwa 4-6 Tagen an. Der Verderb ist gleichermaßen über Propanal, 
Pentanal, Hexanal und Nonanal verfolgbar. Der Zusatz von 150ppm 
Tocopherol verzögert die Entstehung der Verderbsaldehyde signifikant 
(Tabelle 15) und ermöglicht eine bessere Lagerstabilität der 
Formulierungen. 
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1 INTRODUCTION 
Dietary lipids are the major energy source for infants and young 
children. Lipid tissue accretion in growing infants is very high and consists 
of 90% of all energy deposited in the body during the first six months of 
infant’s life (1, 2). The most important functional components of dietary 
lipids (triglycerides, phospholipids and cholesterol esters), practically long-
chain polyunsaturated fatty acids (LCPs) are essential to normal growth 
and the infant development (3, 4). The two families of LCPs, the omega-3 
(ω-3) and the omega-6 (ω-6) have specific functions: docosahexanoic acid 
(DHA; C22:6n-3) in retina and brain, whereas arachidonic acid (AA; 
C20:4n-6) is known to be a precursor of eicosanoids that are important for 
a number of cellular processes.  
AA and DHA are deposited in large amounts in the nonmyelin 
membranes of the developing central nervous system. Adequate supplies 
of ω-6 and ω-3 fatty acids during nervous system development are of 
concern because of possible long-term changes in learning ability and 
reduce visual function (5). Human milk is considered to be the best source 
of fat and dietary essential fatty acids for infant feeding; as it provides a 
complex mixture of fatty acids, including the essential polyunsaturated 
linoleic acid (LA, C18:2n-6) and Alpha-linolenic acid (α-LA, C18:3n-3) and 
LCPs (AA, DHA)(6-8).  
 
Current evidence suggests that the newborn is able to synthesize 
AA and DHA from LA and α-LA, respectively (9). However, the amount of 
LCPs being produced, particularly of DHA, may not be sufficient to meet 
the developmental requirements of the infant, because they have a limited 
desaturation capacity and depends on an exogenous supply of LCPs 
during the first months of life (6, 10). Moreover, a dietary lack of essential 
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fatty acids and their derivatives is evident also in weaned children during 
the second half of their first year of life (11).  
Newborn requirements of the LCPs have been a major focus of 
research for the past decade. The reason for this intense interest was 
based on several observations such as: (a) plasma levels of LCPs 
decrease markedly after birth in formula-fed preterm infants as compared 
to almost constant levels in breast-fed infants of comparable gestational 
age; (b) the level of LCPs in human milk is constant as a function of length 
of lactation or geographical distribution (i.e., nutrition) and therefore to 
what extend can human milk be the gold standard (12); and (c) studies that 
evaluate the effect of formula supplementation with LCPs provide only 
partial answers as to benefit of such supplementation to full-term and pre-
term infants (13). One important question of relevance to infant nutrition is 
whether there are critical neurodevelopmental stages in which DHA is 
required for optimal development (14). However, docosahexanoic acid and 
arachidonic acid are commonly added to infant formula worldwide, but 
dietary concentrations needed to obtain optimal tissue levels have not 
been established. 
 On the light of the fore going observations the objectives of this 
study were; (a) to study the effect of feeding various levels of DHA were (0, 
2, 4, and 6 times those used in infant formulas) on rats growth ; brain, liver 
and plasma fatty acids and phospholipids, (b) to evaluate the effect of 
dietary gamma-linolenic acid (GLA, C18:3n-6) as an intermediate of AA 
synthesis at three levels in the presence of DHA, EPA plus AA (eicosanoid 
precursors) on the fatty acid patterns of tissues, plasma and their 
phospholipids of rats tissues, (c) to report the relationship between mixed 
oils and their antioxidant properties in vivo, (d)  to report  the effect of 
mixed omega 3 and omega 6 feed oils on their radical scavenging activity 
of brain and liver, (e) to assess oxidative stability of both of oils and 
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formulas by monitoring oxidative products and (f) to examine the effect of 
storage on the evolution as volatile secondary products of the oils and 
fractions. 
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2 REVIEW OF LITERATURE 
2.1 Essential fatty acids and functions 
The 'essential' fatty acids were given their name when researchers 
found that they were essential to normal growth in young children and 
animals, whereas mammalian cells lack the ∆ -12 and ∆-15 desaturase 
enzymes (found in most plants) for insertion of a double bond at the ω-6 or 
ω-3 position, but able to synthesize (from non-fat precursors) saturated 
fatty acids and unsaturated fatty acids of the ω-9 and ω-7 series (9, 15). 
Thus, mammalian cells cannot synthesize ω-6 or ω-3 PUFAs de novo and 
must obtain them from the diet. Omega 3 polyunsaturated fatty acids are 
α-LA, EPA and DHA have 3, 5 or 6 double bonds in a carbon chain of 18, 
20 or 22 carbon atoms, respectively. All double bonds are in the cis-
configuration. Linoleic acid and arachidonic acid are essential fatty acids 
(5, 16). Omega 3  and omega 6 essential fatty acids are needed for the 
membranes of all body cells as their role in health is wide reaching: 
encompassing not only healthy heart and brain good function, but also 
playing an important role in the normal function of the eyes, the nervous 
system, the kidney, and the liver, in fact all body systems. Other functions 
also include the contraction of muscles, blood clotting, and inflammatory 
processes (6-8, 17).  
 
2.2 Essential omega 3 and omega 6 fatty acids   requirements 
As macronutrients, fats are not assigned recommended daily 
allowances, it have AI (Acceptable Intake) and AMDR (Acceptable 
Macronutrient Distribution Range) instead of RDAs. The AI for ω-3 is 1.6 
grams/day for men and 1.1 grams/day for women, while the AMDR is 0.6% 
to 1.2% of total energy. The National Institutes of Health recently published 
recommended daily intakes of fatty acids (18); specific recommendations 
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include 650 mg of EPA and DHA, (because both have much greater 
physiological potency than α-LA for protection against coronary heart 
disease), 2.22 g/day of α-LA and 4.44 g/day of LA. This means that the 
ratio of ω-6 to ω-3 is 1.5:1. 
2.2.1 Pregnancy and lactation  
       An adequate intake of DHA and EPA is particularly important during 
pregnancy and lactation periods. During this time the mother must supply 
all the baby's requirements of DHA and EPA because babies are unable to 
synthesize these essential fatty acids themselves. DHA makes up 15 to 
20% of the cerebral cortex and 30 to 60% of the retina, so it is absolutely 
necessary for normal development of the fetus and baby as well (19, 20). 
During pregnancy, the fetus completely depends on maternal sources of 
DHA from lipid stores, maternal diet and nutritional supplements. During 
fetal life, placenta selectively and substantially transports AA and DHA 
from the mother to the fetus. During the third trimester of pregnancy, there 
is an avid accretion of DHA in the liver, brain and retina of the fetus at a 
rate of 4.13 g of EFA per week i.e. 0.59 g/day (18, 21). Pregnancy leads to 
a progressive depletion of maternal plasma DHA, presumably due to the 
increased supply of this critical nutrient to the developing fetal nervous 
system (22, 23). According to WHO and FAO the pregnant woman should 
take at least 2.6 g of ω-3 and 100-300 mg of DHA daily to meet the 
requirements of her fetus (24). In countries where pregnant women 
consume large amounts of fish, it seems to be having beneficial effects for 
the mother: a slightly longer pregnancy (by 1-3 days), slightly larger birth 
weight and also a possible decrease in the risk of pre-maturity (25-27). On 
the other hand, there is some evidence that an insufficient intake of ω-3 
fatty acids may increase the risk of premature birth and an abnormally low 
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birth weight. Also, there is emerging evidence that low levels of ω-3 are 
associated with hyperactivity in children (28-34). 
2.2.2 Infancy and Childhood 
        Once the baby is born, the mother needs a good supply of essential 
omega 3 fatty acids; through eating more oil-rich fish to increase the 
amount of DHA in the breast-milk infants, in order to improve the available 
amounts available for brain, eyes and the nervous system development. It 
is known that, infant and children are generally thought to require 1-2% of 
total dietary energy as LA to prevent EFA deficiency, but pre-term infants 
require at least 10% of this energy (18, 24, and 25). Babies who are born 
pre-maturely and miss out on the umbilical DHA supply during the last 
stage of development are born with low stores of DHA in the brain and 
liver. This can lead to visual impairment and abnormal retina function. 
Thus, pre-mature babies are given extra fatty acids in their feeds to avoid 
this miss function of retina. As these fatty acids are needed for eyesight 
and brain function, there is an evidence, which shows that a lack of DHA in 
the pre-term infant can lead to neurological deficits, such as learning 
disabilities, behavioral problems and perhaps lower scores on IQ 
(intelligence quotient) tests (35, 36). The weaning foods and diets of 
preschool children should contain DHA because metabolic conversion of 
α-LA to DHA is limited to less than 0.2% in children. There is evidence to 
suggest that, 40% of children with attention hyperactivity disorder (ADHD) 
have significantly low levels of plasma ω-3 and DHA (37). Forethere, it is 
recommended that weaning foods should be rich in DHA (fish oil, sea food 
and dry fruits) or supplemented with nutritional supplements containing 
DHA. 
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2.3 Essential omega 3 and omega 6 metabolism 
2.3.1 Conversion of linoleic acid and linolenic acids up to    
         eicosanoid 
       The commonly consumed polyunsaturated fatty acids are LA and α-
LA. Once consumed, these fatty acids can be converted to the longer-
chain, more unsaturated derivatives. Thus, linoleic acid is converted via 
GLA and dihomo-gamma-linolenic (DGLA; 20:3n-6) acids to AA. Likewise, 
α-linolenic acid is converted to eicosapentaenoic acid (EPA; 20:5n-3) 
(Figure 1). There is some controversy about the extent to which DHA can 
be synthesized from EPA in humans (15-17, 38). There are two steps in 
which dietary fatty acids can modulate eicosanoids biosynthesis from AA; 
the first step is a desaturation and elongation and the second step in which 
dietary fatty acids can modulate the biosynthesis of eicosanoids 
(prostaglandins, leucotrienes and thromboxanes by cyclooxygenase and 
lipoxygenase) is at the formations of endoperoxide intermediate (Figure 1). 
EPA as ω-3 can be metabolized by both cyclooxygenase and 5-
lipoxygenase similarly to AA, leading to the formation of trienes 
prostaglandins and the leukotriene 5 series. So, it acts as a competitive 
inhibitor. Thus, increasing ω-3 in diets may reduce AA levels in tissue 
lipids and may decrease the formation of eicosanoid derived from AA 
through inhibiting the oxygenation of AA by cyclooxygenase. (15-17, 38-
39). 
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Figure 1: Metabolic pathway for conversion of the dietary essential fatty acids to 
eicosanoids via the cyclooxygenase (COX) and Lipoxygenase (LOX) pathways. 
 
     2.3.2 Competition between unsaturated fatty acids families 
       The actions of the essential omega 3 and omega 6 fatty acids are best 
characterized by their interactions; they cannot be understood separately. 
In the body, LA competes with α-LA, for ∆6-desaturase, and thereby 
eventually inhibits formation of anti-inflammatory EPA (15, 16). In contrast, 
GLA derives from LA and does not compete for ∆6-desaturase. GLA's 
α- Linolenic acid ω-3 
C 18:3n3
 
Linoleic acid ω-6  
     C 18:2n6 
Docosahexanoic acid DHA 
C 22:6n3 
Arachidonic acid AA 
C 20:4n6 
Dihomo- gammaLinoleic acid DGLA 
C 20:3n6 
Eicosapentanoic acid EPA 
C 20:5n3
 
C 20:4n3 
 γ- Linoleic acid 
 C 18:3n6 
C 18:4n3 
Elongase 
6 aturase 
∆∆  ∆6 Desaturase 
   ∆5 Desaturase 
Omega  fatty acids 
ß-oxidation PG Series 3 
Prostaglandine 
LT Series 5 
Leukotriene 
PG Series 1 
Prostaglandine
 
PG Series 2 
Prostaglandine 
LT Series 4 
Leukotriene 
COX 
COX 
LOX
LOX 
COX 
REVIEW OF LITERATURE 
 13 
elongation product DGLA competes with 20:4n-3 for the ∆5-desaturase. 
Arachidonic acid was derived from DGLA pathway. It sits at the head of the 
"arachidonic acid cascade" more than twenty different signaling pathways 
that control a bewildering array of bodily functions, but especially those 
functions involving inflammation and the central nervous system (15, 40). 
DGLA and EPA compete with AA for accessing to the cyclooxygenase and 
lipoxygenase enzymes. So the presence of DGLA and EPA in tissues 
lowers the output of AA's eicosanoids. For example, dietary GLA increases 
tissue DGLA and lowers thromboxanes B2 (16, 17, 41, and 42) .Likewise, 
EPA inhibits the production of prostaglandins series-2 and thromboxanes 
(40, 43). 
        This competition was recognized as important when it was found that 
leukotrienes were similarly found to be important in immune inflammatory 
system response, and therefore relevant to some diseases like arthritis 
and asthma. These discoveries led to greater interest in finding ways to 
control the synthesis of omega-6 eicosanoids. The simplest way would be 
by consuming more ω-3 and fewer ω-6 fatty acids (17, 44). 
 
2.3.3 Omega 3, omega 6 and eicosanoids  
       Eicosanoids are a family of very potent biological signaling molecules 
that act as short-range messengers, affecting tissues near the cells that 
produce them. In response to hormonal or phospholipase A2, which are 
present in most types of mammalian cells, attacks membrane 
phospholipids, releasing arachidonate from the middle carbon of glycerol. 
Then arachidonate converted to prostaglandins, beginning with the 
formation of prostaglandin H2 (PGH2), the immediate precursor of many 
other prostaglandins and of thromboxanes (Figure. 1). The two reactions 
that lead to PGH2 are catalyzed by a bifunctional enzyme, cyclooxygenase 
(COX), also called prostaglandin H2 synthesis. In the first of the two steps, 
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the cyclooxygenase activity introduces molecular oxygen to convert 
arachidonate to PGG2. The second step, catalyzed by the peroxidase 
activity of COX, converts PGG2 to PGH2 (Figure. 1). Animal studies 
showed that increased dietary ω-3 resulted in decreased AA in brain and 
other tissues (15). Linolenic acid contributes to this by displacing LA from 
the elongase and desaturase enzymes that produce AA (17). EPA inhibits 
phospholipase A2's which releases AA from cell membrane. Other 
mechanisms involving the transport of essential fatty acids may also play a 
role (44, 45). Thus, eicosanoids are involved in reproductive function; in 
the inflammation, fever, and pain associated with injury or disease; in the 
formation of blood clots and the regulation of blood pressure; in gastric 
acid secretion; and in a variety of other processes important in human 
health or diseases (46-49). 
 
2.3.4 Relationship between polyunsaturated fatty acids, lipid 
oxidation and antioxidant. 
  Vitamin E as an antioxidant prevents rancidity of fats in plant 
sources and in the animal’s digestive tract, through inhibiting the oxidation 
of PUFAs in tissue membranes, especially at the cellular level in the 
membranes surround the cells, the sub-cellular particles, and the 
ercythrocytes (50, 51). It also stabilizes the lipid parts of cells and protects 
them from damage from toxic free radical formed from the oxidation of 
PUFAs as well as being an end-product of the oxidation of α-tocopherol, as 
the α-tocopherol quinone is the cofactor for the mitochondrial fatty acid 
desaturation/elongation pathway (51-53). It has been suggested that the 
severe neurological degeneration in patients with a genetic lack of α-
tocopherol transfer protein or abetalipoproteinemia is caused by failure of 
synthesis of long-chain polyunsaturated fatty acids (50, 51). 
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  Figure 2a: Radical chain reaction mechanism of lipid peroxidation. 
 
 
  
Figure 2b: Reaction of tocopherol with lipid peroxides; the tocopheroxyl 
radical can be reduced to tocopherol or undergo irreversible onward 
oxidation to tocopherol quinone. 
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So, the primary function of vitamin E is to help protect the integrity of 
cellular and intra-cellular structures. There is much controversy as to how 
this function is carried out catalytically as a chain-breaking lipophilic 
antioxidant in membranes and plasma lipoproteins? Because the 
tocopheroxyl radical formed by reaction of α-tocopherol with the lipid 
peroxide radical (Figure. 2) can be reduced to tocopherol in three main 
ways by reaction with: (a) Ascorbate to yield the monodehydroascorbate 
radical, this in turn can either be reduced to ascorbate or can undergo 
dismutation to yield dehydroascorbate and ascorbate. There is an integral 
membrane oxidoreductase that uses ascorbate as the preferred electron 
donor, linked either directly to reduction of tocopheroxyl radical or via an 
electron transport chain linked to the oxidation of NADH and succinate 
involving ubiquinone in mitochondria (51, 54). (b) Other lipid-soluble 
antioxidants in the membrane or lipoprotein, including ubiquinone, which is 
present in large amounts in all membranes as part of an electron transport 
chain, not just the mitochondrial inner membrane (53, 54, and 56-58). (c) 
Glutathione is catalyzed by glutathione peroxidase, which is a specific 
isoenzyme (selenoenzyme). Furthermore, selenium has a direct role in the 
recycling of tocopherol (51, 55). 
It is noteworthy that when fat is added to the diet it will destroy the 
vitamin E in both of diet and digestive tract if rancidity occurs. For this 
reason, the quantitative relationship between vitamin E and the amount 
and kind of dietary fat is practical importance. The higher consumption of 
PUFA fat related with higher vitamin requirement (50, 51, 54, and 58). 
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3 MATERIALS AND METHODS 
3.1 Materials 
       Oils were obtained from Henry Lamote GmbH, (Bremen, Germany). 
AIN-93G was obtained from SSNIFF Spezialdiäten GmbH, Soest, 
Germany. Vitamin E standard (α-, δ-, β-, γ-tocopherol) and Folin-Ciocalteu 
reagent were obtained from Merck (Darmstadt, Germany). DPPH; 1, 1-
diphenyl-2-picrylhydrazyl (approximately 90%) was obtained from Sigma 
(St. Louis, MO, Germany). p-Anisidine (4-Amino-anisol; 4-Methoxy-anilin) 
and caffeic acid were from Fluka (Buchs, Swityerland). TMSH; N-
trimethylsulfoniumhydroxide (Macherey-Nagel, Düren, Germany). TEP; 1, 
1, 3, 3-tetraethoxypropane from Sigma (approximately 97%, Steinheim, 
Germany), 2-thiobarbituric acid (TBA), trichloroacetic acid (TCA) and 
butylated hydroxyltoluene (BHT) were from Sigma (St. Louis, MO, 
Germany). Propanal, pentanal, hexanal, octanal and neonanal were 
purchased from Fluka (Steinheim, Germany). Toluene of HPLC grade was 
used throughout the experiment. All other chemicals and solvents were 
from the highest commercial grade and were used without further 
purification. 
 
3.2 Analytical Methods 
   3.2.1 Animals and experimental design 
Long-Evans offspring pregnant rats were acquired at 10-12 day 
gestation from the commercial supplier of Animal House. Only males were 
used in this study to minimize possible effects of hormonal factors. Animals 
were housed and cared there, and then kept in individual cages in a 
thermo-neutral environment at room temperature (26 °C) and 60% relative 
humidity with a cycle of 12 h light and 12 h dark. Each cage was equipped 
with a water bottle with metal lid, a cup for administration attached to a 
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stainless steel plate to avoid over throwing and spillage. Animals were 
placed on a semi-synthetic diet, which was based on the AIN-93G (59). In 
the first Phase, the newborn pups were selected on a random basis for 
each experiment, with mean body weight with no significantly differences. 
Each animal within a particular group was from a different litter and then 
this litter was used as a basis for the number of animals. Rat pups were 
dam-reared until 8 day of age. Dams were fed as described previously 
(60). The artificially hand rearing system was used for pup feeding until 
day 17 when rats were hand fed every 3-4 h. On the day 17-28 (after the 
opening eye), artificial rat milk was fed in a 50 ml water bottle. In the 
second Phase (from 4 weeks to 8 weeks), rats were fed a diet containing 
the similar fatty compositions (Table 1, p 71). 
 
3.2.2 Diets and preparations 
The diets used were modified from AIN-93 G rodent diet (60). The 
dietary oils were a mixture of hydrogenated coconut oil, flaxseed oil, 
rapeseed oil, borage oil and marine oil. The oils were obtained from Henry 
Lamote GmbH, (Bremen, Germany). Coriander oil was cold extracted by n-
hexane. AIN-93G was obtained from SSNIFF Spezialdiäten GmbH (Soest, 
Germany). All formulas were prepared to provide about 15 % LA, 3 % α-
LA, 0.58% AA and 0.89% EPA of dietary fat in omega-3 and omega-6 
groups, with the exception of deficient group (control only contained 15 % 
LA and 3 % α-LA of dietary fat). The omega-3 group contained three levels 
of docosahexanoic acid (DHA): 1%, 2% and 3 % DHA, while the omega-6 
group contained 1%, 3% and 5% gamma-linolenic acid (GLA). 
Compositions of dietary fat used oils in the experiment were determinate 
by gas chromatography analysis.  
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3.2.3 Lipid extraction and separation of phospholipids from 
         the tissues and plasma 
        At four time points, rats were killed and the liver and brain were 
removed from the body and collected, washed three times in ice cold 
saline, blotted dry and weighed. Lipids were extracted according to Folch 
et al. 1957 (61). The organs were homogenized with twenty fold volume of 
dichloromethane: methanol (2:1, v/v) containing 10 mg of buthylated 
hydroxytoulene (BHT)/L as an antioxidant, which was then flushed with 
nitrogen and left to be extracted overnight at 4 °C . The homogenate was 
filtered and washed with additional 10 ml of solution mixed with 20 ml of 
0.85% sodium chloride (v/v), shake and left to partition overnight at 4°C. 
The lower organic phase was transferred and evaporated. Extracts were 
combined and dried under a steam of nitrogen. Blood was collected, 
transferred to a plastic tube containing EDTA, centrifuged at 3000 rpm at 
4°C. An aliquot of the upper-phase (plasma) was tra nsferred to another 
tube. For lipid extraction from plasma 500 µL plasma was mixed with 
ethanol containing 0.005% BHT (500 µL) and extracted with hexane (2 ml) 
after manually shaking for 3 min (62). Phospholipids were obtained for 
application on silica gel plates (thickness = 0.25 mm; Merk, Darmstadt, 
Germany) activated at 120°C for two hours immediate ly before use. Plates 
were developed with chloroform: methanol: acetic acid: water (25: 15: 4: 2, 
by volume) (63), after visualization with 2, 7-dichlorofluorescein, 
phospholipids band was isolated and transmethylated. 
 
3.2.4 Lipids transmethylation and gas chromatography 
A portion of total lipid extracts from each tissue was transmethylated 
using methanol (1% H2SO4 in methanol) for three hour at 70°C (64). After 
cooling the resulting fatty acid methyl esters (FAME) were extracted with n-
hexane, dried with anhydrous sodium sulfate and then concentrated to a 
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small volume with a steam of nitrogen and transferred to micro vials for 
gas chromatographic (GC) injection, whereas phospholipids were 
transmethylated, phospholipids band was isolated and transesterified into 
their methyl esters (FAME) using N-trimethylsulfoniumhydroxide (TMSH), 
methyl esters were extracted twice into one ml hexane and the combined 
extracts were dried with steam nitrogen. 
The fatty acid methyl esters were then identified and quantified on a 
Shimadzu GC-14A equipped with flame ionization detector (FID) and C-
R4AX chromatopac integrator (Kyoto, Japan).The samples were separated 
on a 30m SP™ -2380 capillary column (Supelco, Bellefonte, PA, USA: 
0.25 mm diameter, 0.2 µm film thickness) using helium at a flow rate of 0.6 
ml/ min with a spilt ratio of 1:40. The chromatographic run parameters 
included an oven starting temperature of 100°C that  was increased by the 
rate of 5°C/min to 175 °C and then were held for 10  min before increasing 
to 220°C at 8°C/min, with a final hold of 10 min .T he injector and detector 
temperatures were both constant at 250°C. Peaks wer e identified by 
comparison of retention times with external standard mixture (Sigma, St. 
Louis, MO, USA; 99% purity specific for GLC) on the same conditions. 
 
3.2.5 Determination of tocopherols by NP-HPLC 
 3.2.5.1 Apparatus and chromatographic conditions 
         Separations were accomplished on a NP-HPLC with Lichrosorb Si 
60, 5 µm (250 *4 mm, i.d.) analytical column from Knauer (Berlin, 
Germany). Isooctane: acetyl acetate 96:4 (v/v) were used as a mobile 
phase and delivered at a constant flow rate of 1.0 ml/ min with column 
back-pressure of about 65–70 bar. The used solvent delivery module was 
LC-9A from Shimadzu HPLC (Kyoto, Japan), while the chromatographic 
system included a Model 87.00 variable wavelength monitor detector from 
Knauer, Berlin, Germany. The solvent system selected, retention time, and 
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UV detection of eluting components are shown in Table 2a. The (20 µL) 
diluted oils solution (20-30 mg in 1ml) of the selected mobile phase) was 
directly injected onto the HPLC column. Tocopherols were identified by 
comparing their retention times with those of authentic standards. 
 
3.2.5.2 Standard curves preparation 
          Standard solution of vitamin E (50 mg/L), were prepared in n-
hexane. The standard solutions were stable at least one month at 4º C in 
an argon atmosphere. Fresh working standard solution was prepared daily 
by approximate dilutions of standards in mobile phase solution. Twenty µL 
were injected four times into the HPLC system and the peak areas were 
determined to generate standard curve data.  
 
Table 2a: Linearity in studied vitamin E by NP-HPLC at 295 nm. 
 
Compound RT (min)* R2** Equation curve*** 
α-Tocopherol 9 0.9989 y =  10436 x - 141.48             
ß-Tocopherol 13 0.9996 y =  11396 x - 5152.4             
γ-Tocopherol 15 0.9967 y =  12124 x - 118.88             
∆-Tocopherol 20 0.9935 y =  12224 x - 3532.6             
*    Rt, retention time 
**  Determination coefficient 
*** X, concentration (µg/ml); y, peak area 
 
Slope of standard curves (six concentrations levels) were obtained 
by linear regression. Shimadzu C-R6A chromatopac integrator was used 
for all quantization based on peak areas. 
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3.2.6 Radical Scavenging Activity of total lipids from brain 
         and liver against  DPPH  radicals   
         The reduction of toluenic solution of DPPH was examined radically in 
the presence of hydrogen donors in total lipids from brain and liver. Briefly, 
freshly made DPPH radical at a concentration of 0.0001 M in toluene was 
added into toluene solutions of total lipids from brain and liver to start the 
reaction. For determination, ten mg (in 100 µL toluene) of total lipids from 
brain or liver were mixed with 390 µL toluenic solution of DPPH radicals 
and the mixture was vortexed for twenty seconds at ambient temperature. 
The possible dilution in the cuvette was taken into account wherein the 
final volume in all of the assays was 400 µL. The absorbance at 515 nm 
was measured in 1-cm quartz cells using UV-260 visible recording 
spectrophotometer (Shimadzu, Kyoto, Japan) against a blank of pure 
toluene after the reaction was carried out at ambient temperature for 60 
min (65). Radical DPPH scavenging activity was estimated from the 
difference in absorbance with or without sample and expressed as percent 
DPPH inhibiting. All tests were conducted in triplicates. 
   
3.3. Oxidative stability of oils and formulas during storage 
  3.3.1 Chromatographic Purification. 
 
 Control oil (Table 1) was purified chromatographically to remove 
tocopherols and other antioxidants and carotenoids by the following 
procedure. A glass column was packed with a hexane slurry of 14 g of 
high-purity Merck silica gel (grade 60, 230-400 mesh, activated overnight 
at 120 °C), followed by a hexane slurry of 4 g of a ctivated carbon (100-200 
mesh, Sigma Chemical Co., St. Louis, MO), and then was washed with 
hexane. A 3.0 g of oil was passed through the column and eluted with 200 
mL of hexane, followed by 100 mL of 10% ethyl ether in hexane (v/v). The 
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chromatographed oil recovered in 98% yield was not significantly changed 
in fatty acid composition. Another control was used containing 150 ppm α-
tocopherol.  
 
3.3.2 Preparation of the emulsions and samples 
Oil-in-water emulsions contained ten percent oil and one percent 
lecithin and were prepared by a previously described procedure with a 
slight modification (66) using a phosphate buffer (25 mM, pH 3.8), and 
then were added to AIG 93G free fat diet, mixed for ten min as well as 
freeze-dried, packed and sealed under vacuum condition for omega 3 and 
omega 6 formula oils (1% DHA with1% GLA, 3% DHA and 3% GLA). All 
samples were placed in the oven at 60ºC for storage study. 
 
3.3.3 Determination of Total Phenolic Compounds (TPCs) 
TPCs were quantified colorimetrically using Folin-Ciocalteu reagent. 
Folin-Ciocalteu was diluted thirty fold in distilled water. Aliquots of oil (2 g) 
were dissolved in five ml n-hexane and mixed with ten ml methanol 
solution (80%) in glass tubes for two min in a vortex and then were 
centrifuged at 3000 rpm for 10 min. The extracts were combined and 
concentrated in vacuo at 30ºC until consistency was reached. After 
purification with acetonitrile, 0.2 ml and one ml diluted Folin-Ciocalteu was 
added, the flasks were shaken vigorously. After three min, 0.8 ml of 20% 
Na2C03 were added and the mixtures were mixed thoroughly again. The 
mixtures were allowed to stand for one hour protected from light. The 
absorbance of the blue color produced was measured at 765 nm using a 
UV-260 visible spectrophotometer (Shimadzu, Kyoto, Japan).The 
concentration of the total phenolic compound for each extract  was 
expressed as caffeic acid  in parts per million based on the calibration of 
standard (six serial in triplicate). 
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3.3.4 Lipid Classification by column chromatography (CC) 
Oils and recovered oils in chloroform were separated into the 
different classes neutral lipids (NL), glycolipids (GL) and phospholipids 
(PL) by passing through a glass column (20 mm dia * 30 cm) packed with 
a slurry of activated silicic acid (65- 230 mesh; Merck) in chloroform (20 %, 
w/v) according to Rouser el al. (67). NL was eluted with three times the 
column of chloroform, but GL and PL were eluted with five and four times 
of acetone and methanol, respectively. 
 
3.3.5 Peroxide, anisidine and conjugated diene values   
Measuring progress of oxidation levels of the oils during storage 
period was followed by determination of primary and secondary oxidation 
products through changes in fat peroxide (AOCS Cd 8-53), whereas was 
assayed by indirect titration with sodium thiosulfate, and the iodine 
resulting from the oxidation of iodide by peroxides was measured. The oil 
sample weight in the range of 0.2- 0.5 g was used. Also, a blank assay 
was carried out. Peroxide values (PV) are expressed as mill moles (mmol) 
of active oxygen per kg of oil; as well as p-anisidine (AOCS Cd 18-90) and 
conjugated dienes and trienes were expressed as absorptitivies of the one 
percent oils in isooctane at 232 and 270 nm. All tests were conducted in 
triplicate and averaged. No significantly statistic difference (P> 0.05) was 
found among the replicated experiments. 
 
3.3.6 Characterization of thiobarbituric acid reactive substrate and 
free radical activity 
Compounds’ reacting with thiobarbituric acid (TBA) was determined 
by the described Pegg’s method (68), with slight modification. Twenty µL 
butylated hydroxyltoluene (BHT) (to prevent oxidation during the assay) 
were added to 100-200 mg oil, two ml 10% (wt/v) trichloroacetic acid (TCA) 
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in water and two ml 0.6% (wt/v) TBA in 0.25 M HCL. The tubes were 
shaked and heated at 80ºC in a water bath for one hour, left to cool at 
room temperature and centrifuged 3000 rpm  for 20 min. Calibration curve: 
0, 20, 40, 100, 150 or 200 µL 0.1 nM 1, 1, 3, 3-tetraethoxypropane (TEP), 
an MDA precursor, was completed to 2ml with water. The procedure 
described for samples was then applied. According to color intensity, as an 
indicator of malondialdehyde (MDA) content, malondialdehyde was 
measured at 532 nm, using a Shimadzu UV-260 (Kyoto, Japan) 
spectrophotometer. Radical scavenging activity of oils and their fractions 
were examined by reduction of DPPH in toluene.  (See details 3.2.6).  
 
3.3.7 GC-HS analysis of chosen secondary oxidation products 
Oils and oils fractions (NL, GL and PL) were carried into special 
headspace vials sealed with silicone rubber Teflon caps with a crimper. 
Oils were heated at 60ºC for 17 min and the head gas phase was injected 
for 60-90 seconds in HS-GC (a Hewlett–Packard 5890) with FID detector 
and split/splitless injector. Chromatographic separation of butanal, 
pentanal, hexanal, octanal and neonanal were carried out using a DB-1701 
column (30 m length, 0.32 mm i.d., and 1µm film thickness; J & W 
Scientific, Folsom, CA). The oven temperature was 40ºC for 10 min, 
followed by temperature programming to 210 ºC at 4ºC/min and then was 
held for 10 min. The FID temperature was 300ºC and the injection port was 
held at 280ºC. Helium was used as the carrier gas. Peaks were identified 
by comparison of retention times with external standard mixture (Fulka, 
99% purity specific for GLC) on the same conditions. Results were 
calculated in micro moles per kilogram of oil. 
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Table 3b: Linearity in studied propanal, pentanal, hexanal and nonanal by 
GC-HS. 
 
Compound RT (min)* R2** Equation curve*** 
Propanal 4.9 0.994 y =  66233 x - 12490           
Pentanal 7.7 0.998 y =  52444 x - 19676             
Hexanal 11.3 0.998 y =  36956x + 2730 
Nonanal 24.1 0.997 y =  2900.6 x + 848.12             
*  Rt, retention time 
** Determination coefficient 
*** X, concentration (µg/g); y, peak area 
 
 
All rats fatty acids compositions are expressed as mean ± SD. Least 
significance Difference was used to compare the different of means 
between samples. Differences were analysis with the Correlation 
coefficient and SPSS 12.0 for windows. Statistical were considered 
significantly at a value of p < 0.05. 
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 RESULTS AND DISCUSSION                                          
Part I Animal experiment 
4.1 Effect of feeding on the weight and fatty acid composition 
4.1.1 Impact of feeding on rat’s growth 
Experimental rats’ growth showed a slight increase in body weight of the 
3% DHA group than another 1% DHA and 2% DHA groups at days 3, 6 until 56. 
Body weights at day 56 were 178, 183 and 196 g for the 1% DHA, 2% DHA and 
3% DHA omega 3 groups, respectively. On the other hand, there were no 
significant differences in rat weight gains in omega-6 group (Figure 4, p 85). 
Hence, it could be concluded that high levels of DHA in the omega-3 diet may 
result in an increase in body weight of the experimental animals (69). 
 
4.1.2 Impact of feeding on liver weight and fatty acids composition 
4.1.2.1 Omega-3 group 
Liver fatty acids composition (Table 3, p 72), as affected by different 
levels of GLA along with eight weeks, reflected more biological variability in 
the liver. It has been reported that, liver cells are the main site for the 
biosynthesis of LCPs from 18 carbon precursors, and for the formation of 
lipoproteins that transport fatty acids in the plasma and uptake by most 
other cells (70 and 71). LA was found to be higher (11.6%- 16.2%) than 
that obtained in brain of all studied groups (0.8%- 1.53%) after 4 weeks 
and 8 weeks. However, as dietary DHA increased, LA was increased after 
8 weeks (11.6%, 14.4% and 16.2% in 1%, 2% and 3% DHA groups, 
respectively) and AA decreased (10.5%, 9.88% and 9.72% in the same 
order). These findings were supported by Laidlaw and Holub (72) and 
Jensen et al. (73) that high levels of dietary DHA may inhibit ∆5- and ∆6- 
desaturase activity and thereby decrease the formation of AA from LA. α-
LA was found to be 0.12% at birth , then significantly increased to 0.45% 
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and 0.52% after 4 and 8 weeks, respectively in control group, but this 
amount was insufficient to meet the developmental requirements. This can 
be emphasized by the low level of DHA (5.86%) at birth and after 4 and 8 
weeks (4.93% and 6.03%, respectively). On the other hand, although α-LA 
was not detected in all omega-3 groups after 4 weeks (may be due to the 
complete conversion to another omega-3 metabolic product or DHA, it was 
detected in decreased levels about 58.4, 66.7% and 33.3% in 1%, 2% and 
3% DHA, respectively after 8 weeks compared to that obtained at birth 
0.12%). However, it reflects high ∆6- and ∆5- desaturase activity to the 
formation of C20:4n3, EPA and DHA from α-LA. 
In regard to C18:4n3 and EPA which intermediate DHA synthesis, 
the results illustrated that C18:4n3 was not detected in the profile of liver 
fatty acids at birth and after 4 and 8 weeks in control group, may be due to 
the formation of EPA from C18:4n3, particularly in the presence insufficient 
amount of DGLA. It was reported that, DGLA competes with C20:4n3 
(C18:4n3 elongation product) for the ∆5- desaturase and inhibit formation 
of EPA, DHA and eicosanoids from EPA. In the other interpretation in the 
body, LA ca competes with α-LA for ∆6- desaturase and thereby eventually 
inhibits formation of C18:4n3, C20:4n3, EPA, DHA and eicosanoids (15 
and 16). After 8 weeks, C18:4n3 was detected with insignificantly 
differences between omega-3 groups (0.29%- 0.46%), which may be 
attributed to the conversion of α-LA into C18:4n3. 
EPA significantly showed lower level at birth (0.31%), compared to 
those obtained after 4 weeks (1.49%- 5.52%) and (0.45%- 2.19%) after 8 
weeks in all groups. After 8 weeks, 3%DHA group illustrated the highest 
significantly EPA level (2.19%) and followed by 2%DHA group (1.39%), 
1%DHA group (0.76%) and control group (0.45%). However, the 
increasing of C18:4n3 and EPA compared to that obtained at birth can be 
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referred to the metabolism of α-LA, and this is in agreement with Sastry 
(74), Lands (75) and Salem (76). 
Liver DHA level was found to be 5.86% at birth and then significantly 
increased to 6.03% in the control group and to 13.9%-14.8% in omega-3 
groups after 8 weeks, with significantly differences between groups. The 
data also showed that 3%DHA group had the highest DHA level (14.8%) 
followed by 2%DHA group (14.3%) and 1%DHA group (13.9%). On the 
other hand, the lowest DHA level and the increase in n-6 PUFA in the 
control group reflects the low available supply of DHA to the nervous 
system, but by contrast after 8 weeks, DHA was increased with increasing 
LCPn-6 to 23.8%, 26.1% and 27.6% in 1%, 2% and 3% DHA, respectively 
depending on the biological behavior in liver and dietary supplementation. 
As previously mentioned, depending on inhibition of ∆6- and ∆5-
desaturase activity, the results showed that , as DHA level increased in the 
diet, AA levels significantly decreased. Wherefore in 1%, 2% and 3% DHA 
groups after 8 weeks, compared to that obtained after birth (19.8%). 
In general, all groups showed very similar profile of liver fatty acids 
after 8 weeks, which composed of 38.6%- 40.7% SFA, 12.4%- 22.7% 
MUFA and 38.7%- 46.9% PUFA of total fatty acids; and 8.24%- 19.2% as 
oleic acid which represents 53.1%- 84.6% of total MUFA. AA/ LA, DGLA/ 
AA and n-3/n-6 ratios reflect the change in enzymatic activities. The high 
ratios of n-3/ n-6 after 8 weeks in omega-3 groups compared to that 
obtained from control group, but with comparatively higher levels in 
3%DHA group. 
AA/ LA and DGLA/ AA ratios reflect the change in the ∆6- and ∆5-
desaturase activity in all groups. After 8 weeks, control group had higher 
levels of AA/ LA and DGLA/ AA (1.23% and 423.3%, respectively) 
compared to that obtained after 4 weeks. The higher ratios of AA/ LA and 
DGLA/ AA can be due to EPA, which acts as competitive inhibitor that 
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decreases the formation of eicosanoids by inhibiting oxygenation of AA 
(cyclooxygenase and lipoxygenase pathways). On the other hand, AA/ LA 
and DGLA/ AA were decreased about 31.1% and 66.6%, respectively in 
1%DHA group; 16.7% and 37.5%, respectively in 2%DHA group; and 
25.9%- 24.6%, respectively in 3%DHA group after 8 weeks compared to 
the ratios at 4 weeks, but with comparatively higher AA/ LA (0.9) and 
DGLA/ AA (7.0) ratios after 8 weeks in 1%DHA group. This finding reflects 
the effect of added EPA to diet that inhibits ∆5- desaturase activity and 
thereby the formation of AA from DGLA (77). A DHA/EPA ratio reflects the 
changes in the DHA status in all groups. After 8 weeks, the ratio was 
increased by about zero, 191.7%, 81.8% and 273.5% compared to that 
obtained after 4 weeks in control, 1%, 2% and 3% DHA groups, 
respectively. The increase in DHA/EPA ratio reflects higher β-oxidation on 
elongation EPA products to produce DHA. The average liver weight after 
one week was 0.40 g with increasing to 8.00, 8.47 and 8.20 g in the 1% 
DHA, 2% DHA and 3% DHA group after 8 weeks, respectively. 
 
4.1.2.2 Omega-6 group 
It has been reported that GLA reduces body fat content but not body 
mass and facilitates fatty acid β-oxidation in the liver (78). In the present 
study, the average liver weight after the first week was 0.40 g; whereas, 
the relative weights of liver to total body weights were 4.4%, 4.6% and 
4.1% for 1% GLA, 3% GLA and 5% GLA group after the fourth week, 
respectively; with no significant difference at the end point. 
Concerning liver fatty acids profile (Table 4, p 73), as affected by 
different Levels of DHA during 8 weeks of age; the data revealed that, LA 
acts as precursors to LCPsn-6, had higher levels in liver (11.6%- 13.8%) 
than that obtained in brain of omega-3 and omega-6 groups at birth and 
after 4 and 8 weeks. In respect to omega-3 and omega-6 groups, the 
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results showed that, 1%DHA and 1%GLA groups have the same LA level 
(11.6%) after 8 weeks, but 3% and 5%GLA groups showed lower levels 
(12.7% and 11.6%, respectively) compared to those obtained in 2% and 
3%DHA groups (14.4% and 16.2%, in the same order). The reduction of 
LA level in 3% and 5%GLA groups is due to the following, LA competes 
with α-LA for ∆6- desaturase, and thereby evenly inhibits formation of EPA 
(0.25% and 0.34%, respectively) than those obtained in 2% and 3%DHA 
groups (1.39% and 2.19%, in the same order), this result is supported by 
Chapkin (15); Calder and Field (16). With references to liver omega-6 
groups, the result showed that, as dietary GLA increased up to 3%, LA and 
AA increased, then decreased in 5%GLA group, but with higher AA levels 
than in 1%GLA group. Wherefore, 3%GLA groups showed the highest LA 
and AA levels (12.7% and 24.1%, respectively) and followed by 5%GLA 
group (11.6% and 21.2% in the same order), and 1%GLA group (11.6% 
and 15.6%, respectively). The higher  formation of AA in 3%GLA and 
5%GLA groups accompany with lower DHA levels after 8 weeks mean 
that, DGLA compete with omega-3 fatty acids for the ∆5- desaturase to 
produce AA, and thereby inhibition/ or production of lower DHA. On the 
other hand, the lower formation of AA in 5%GLA group compared to that in 
3%GLA group may be attributed to the presence of GLA, DGLA, 
prostaglandin E1 and 15-hydroxy-eicosatrienoic acid or to the metabolic at 
∆5- desaturase step mostly appeared to be of low enzymatic activity in the 
synthesis of LCPs n-6 fatty acids (79). Moreover, AA/LA and DGLA/AA 
ratios (provides a biochemical indexes of product-substrate relationship in 
the LCPs n-6 pathway and ∆5-6 desaturase activity) has emphasized the 
same results of AA in omega-6 groups, in which 3%GLA group showed the 
highest AA/LA and DGLA/AA ratios (1.89% and 14.9%, in the same order) 
and 1%GLA group (1.34% and 10.4%, respectively) after 8 weeks. The 
results of EPA/AA support the foregoing findings, in which 3%GLA group 
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the lowest EPA/AA ratio and followed by 5% and 1%GLA groups at the 
end of experiment. 
DHA/EPA ratio reflects the biochemical synthesis of DHA by β-
oxidation, in which 3%GLA group showed the highest ratio (21.7) and 
followed by 5%GLA group (12.7), and 1%GLA (10.7) after 8 weeks. This 
result showed that, 3%GLA group possesses the highest capacity of 
converting the LCPn-3 especially DHA from its dietary precursors. The 
higher ratio of n-3/n-6 in 1%GLA group (0.37) after 8 weeks reflects the 
higher enzymatic activity, which reserves a normal brain behavior through 
n-3 status (59). However, high dietary levels of GLA (3% and 5%) resulted 
in higher levels of AA and lower EPA and DHA levels after 8 weeks. 
Generally, omega-6 groups illustrated similar profile of liver fatty acids, 
composed of 41.3%- 44.2% SFA, 15.3%- 20% MUFA, 39.5%- 45.7% 
PUFA of total fatty acids and 9.05%- 11.9% oleic acid, which represents 
19.8%- 30.1% of MUFA.  
 
4.1.3 Impact of feeding on plasma fatty acids composition 
4.1.3.1 Omega-3 group 
 Effect of supplement of different levels of DHA on the content of 
plasma fatty acids, along 8 weeks and presented in tables 5 (p 74). It’s well 
known that, after the biosynthesis of the fatty acids and the formation of 
lipoproteins in liver cells, the latter transports the fatty acids through 
plasma and uptake by most cells (70 and 71). Wherefore, the profile of 
plasma fatty acids showed that, LA and α-LA, which acts as precursors for 
LCPs n-6 and n-3 were found in higher levels (21.1%- 14.3% for the former 
and 4.41%-1.56% for the latter) than those obtained in liver and brain of 
omega-3 and omega-6 group, it can be seen that, as dietary DHA 
increased up to 3%, LA levels increased and AA levels decreased, but with 
higher LA(21.1%) and lower AA (4.37%) in DHA group means that, 
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increasing omega-3 in the diet may reduce AA levels (15-17 and 38-39), in 
which α-LA and C20:4n3 compete with LA and DGLA on ∆6- and 5- 
desaturase, and thereby production of higher EPA (2.09%). The EPA 
competes with the lower level of AA for accessing to the cyclooxygenase 
and lipoxygenase to produce EPA’s eicosanoid, and thereby formation of 
the lowest DHA (4.85%). Contrarily, 1%DHA group showed the lowest LA 
and EPA levels and the highest α-LA, AA and DHA. This can be explained 
on the basis that, the reduction of LA level is due to the competition of α-
LA for ∆6- desaturase, and thereby reduces the formation of EPA (1.04%) 
and increases AA (8.93%) and α-LA (4.41%). Furthermore, the higher level 
of DHA was to be accompanying with decreasing EPA. However, 2%DHA 
group behaves between 1% and 3% DHA groups. The results of AA can 
be emphasized by the results of AA/LA and AA/DGLA ratios, in which 
3%DHA group had the lowest levels (0.21% and 5.14%, respectively), 
followed by 2%DHA group (0.41% and 9.03%, in the same order) and 
1%DHA group (0.62% and 16.54%, respectively) after 8 weeks. 
The results of DHA can be explained by DHA/EPA ratios, which 
reflect the biosynthesis of DHA from EPA in which 3%DHA group had the 
lowest DHA level (2.32%) and followed by 2%DHA (3.52) and 1%DHA 
group (6.68) after 8 weeks. This result showed that, 1%DHA group 
possessed the highest capacity of converting the LCPs n-3 especially DHA 
from its dietary precursors. 
The results of EPA/AA ratios supported the foregoing results, in 
which 3%DHA group had the highest ratio (0.48) and followed by 2%DHA 
(0.22) and 1%DHA group (0.12) after 8 weeks. The higher ratio of n-3/n-6 
in 1%DHA group (6.57) after 8 weeks reflects the higher enzymatic activity. 
However, plasma omega-3 groups presented similar profile of fatty acids, 
composed of 39.4%- 41.4% SFA, 20.2%- 23.2% MUFA, 37.2%-38.3% 
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PUFA of total fatty acids after 8 weeks. Palmitic acid was detected (24.7%-
26.8%) as a major component (62.7%-66.5%) of SFA. 
 
4.1.3.2 Omega-6 group 
Tables 6 present the effect of different levels of GLA on plasma fatty 
acids, along with eight weeks. As mentioned elsewhere, lipoproteins 
transport fatty acids, in particular, LCPs by plasma to most cells (70 and 
71). Wherefore, LA and α-LA, which consider as precursors for LCPs n-6 
and n-3 were found to be in higher levels (ranged between 19.3% to 20.2% 
for LA and 1.18% to 1.41% for α-LA) than those obtained in liver and brain 
of omega-6 and control group. 
In respect to plasma LA, as dietary GLA increased LA level in 
significantly decreased, but with significantly increase in 5%GLA group 
than that of 3%GLA group, after 8 weeks. This may be attributed to the 
effect of intestinal up take of GLA (1.41%-1.3% in 3% and 5%GLA groups, 
respectively) after 8 weeks. The results revealed that, there were 
insignificant differences in DGLA level between all omega-6 groups after 8 
weeks. Plasma AA, showed that 3% and 5% GLA groups had significantly 
higher levels of AA (13.4%- 13.5%) than that obtained in 1%GLA group 
(12.2%), but with significantly lower levels than obtained in control 
group(24.2%) after 8 weeks. The highest level of AA in control group 
accompany with the lowest EPA level (0.48%) and the highest DHA level 
(4.5%), after 8 weeks reflect the competitive effect of DGLA with C20:4n3 
for ∆5- desaturase, and thereby, the formation of AA. The significant higher 
AA levels accompany with the highest EPA and the lowest DHA in 3%GLA 
and 5%GLA groups compared to that obtained in 1%GLA after 4 weeks, 
means that at higher dietary levels of GLA, DGLA compete with C20:4n3 
for the ∆5- desaturase to produce higher AA. The highest EPA and the 
lowest DHA, reflect the slower formation of DHA. On the other hand, the 
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reduction formation of plasma AA in 1%GLA group than that in other 
omega-6 groups, reflects the combination effect of EPA (1.18%), DHA 
(3.05%), which lead to suppress the formation of AA and the inflammatory 
mediator Leukotrienes in the plasma, because EPA blocks ∆5- desaturase 
activity, the terminal enzymatic step in AA synthesis (77). These findings 
were also reflected in the calculated AA/LA in which 1%GLA group had the 
lowest ratio (0.6). Plasma DHA was found at significant higher 
concentration in 1%GLA group than those of 3% and 5%GLA groups, 
which could be supported by the highest DHA/EPA ratio (2.58) in 1%GLA 
group after 8 weeks. The highest DHA level (3.05%), DHA/EPA (2.58) and 
n-3/n-6 (0.21) in 1%GLA group, and the lowest AA level (12.2%) and by 
AA/LA ratio (0.60) reflect the competition between the metabolic pathways 
between w-3 and w-6 fatty acids (80-83). However, palmitic acid was found 
as a major component on of SFA in all groups, with significant reverse 
relationship between PUFA n-3 and PUFA n-6 at all experimental periods. 
 
4.1.3 Impact of feeding on brain weight and fatty acids  
4.1.3.1 Omega-3 group 
 
 The average brain weight of the 1st week was 0.75 g, increased to 
1.42 g in 1% DHA and 1.65 for both of 2% and 3% DHA omega 3 groups 
with brain to body weights ratios were 0.0079, 0.0086 and 0.0084 at the 
end of the experiment. 
In respect to brain fatty acids composition, as affected by different 
levels of DHA during 8 weeks of age (Tables 7, p 76).α-LA  levels 
(C18:3n3) showed significant higher levels in all groups (0.41%- 0.52%) 
after 8 weeks, compared to that obtained at birth (0.15%). The 
comparatively higher levels of α-LA after 8 weeks can be attributed to the 
exogenous supply of α-LA to the diets. On the other hand, the insignificant 
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difference between α-LA level at birth and after 4 weeks (0.06%) means 
that, the amount of α-LA almost completely used in the metabolic pathway.  
The intermediate C18:4n3 and EPA (C 20:5n3) of DHA metabolite 
were detected in the profile of brain fatty acids. Although C18:4n3 was not 
detected at birth it showed significantly higher levels in all groups, with 
comparatively higher levels in omega-3 groups after 4 and 8 weeks. The 
higher levels of C18:4n3 was found to be 2.33, 2.42 and 2.21 fold in 1%, 
2% and 3% DHA groups, respectively more than that obtained in control 
group after 8 weeks. This can be attributed to the conversion of the 
supplemented from α-LA to C18:4n3. 
In regard to EPA, the results showed significantly lower level at birth 
(0.24%) compared to those obtained after 4 and 8 weeks in all groups 
(0.44%-0.49% and 0.45%- 1.78% respectively). After 8 weeks, it could be 
noted that, 3% DHA group has the highest EPA (1.78%) followed by 2% 
DHA groups (1.07%) and 1% DHA group (0.45%). However, control group 
and 1%, 2% and 3%DHA showed higher levels of EPA by about 4.46, 
1.88, 4.46 and 7.42, respectively fold more than that obtained at birth 
(0.24%). Increasing C18:4n3 and EPA in all groups compared to that 
obtained at birth refers to the metabolism of α-LA, and this is agreement 
with Sastry (74), Lands (75) and Salem (76). 
Brain DHA level was found to be 6.05% at birth, then significantly 
increased to 6.55% in control group and to 13.9- 14.4% in all groups after 
8 weeks, but with no significant differences between omega-3 groups. This 
results are consistent with the observations of Pawlosky at al.(84), who 
reported that, a human who consume a high omega-3 have a low rate of 
conversion of DPA n-3 to DHA. 
As expected, depending on inhibition of ∆5- and ∆6- desaturase 
activity as DHA level increased in diet, it was found that AA (20:4n6) 
significantly decreased after 4 and 8 weeks and by about 18.6%, 24.9% 
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and 30.2% after 8 weeks in 1%, 2% and 3% DHA groups, respectively 
compared to that obtained at birth (12.9%). However, rats in all groups 
showed similar profile of fatty acids composition, which contains 44.6%- 
54% SFA, 23.4%- 26.7% MUFA and 20.1%- 29.9% PUFA. 
The higher ratio of n-3/n-6 in all groups, after 8 weeks compared to 
those obtained after 4 weeks, with comparatively higher levels in omega-3 
groups reflect the enzymatic activity, which reserve a normal brain 
behavior through n-3 status (59). 
AA/ LA and AA/ DGLA ratios illustrate the changes in AA status in all 
groups. Control group showed higher levels of AA/ LA and AA/ DGLA after 
8 weeks by about 26.9% and 593.8%, respectively than that obtained after 
4 weeks. This higher ratios can be attributed to the higher level of EPA 
(1.07%), which consider as competitive inhibitor that may decreases the 
formation of eicosanoids through inhibiting oxygenation of AA by 
cyclooxygenase (COX) and lipoxygenase (LOX) pathways (15-17 and 38-
39). On the other hand, in omega-3groups, AA/LA was decreased in 1% 
and 2% DHA groups by about 13.8% and 0.33%, respectively, but it was 
increased in 3% DHA group by about 6.88% after 8 weeks than that 
obtained after 4 weeks. Furthermore, AA/ DGLA was decreased by about 
35.5, 58.7 and 61.5% in 1%, 2% and 3% DHA groups, respectively after 8 
weeks compared to that obtained after 4 weeks. This means that, addition 
of EPA inhibits the activity of ∆5- desaturase and thereby, decreases the 
formation of AA from DGLA (77 and 87). 
The results of DHA/ EPA ratio, which reflects the changes in DHA 
status, showed that, after 8 weeks DHA/ EPA was increased by about 
14.7% in 1% DHA group, but decreased by about 50.4% and 72.5% in 2% 
DHA and 3%DHA, respectively compared to those obtained after 4 weeks. 
The decrease in DHA/ EPA ratios shows lower β-oxidation to produce DHA 
and/ or modulation to eicosanoids synthesis from EPA by cyclooxygenase 
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and lipoxygenase. On the other hand, the increase in DHA/ EPA reflects 
higher β-oxidation to produce DHA. 
 
4.1.3.2 Omega-6 group 
 
The average brain weight after the 1st week was 0.75 g and after 28 
days, the relative weights of brain to total body weights were 1.69%, 1.48% 
and 1.55% for the 1% GLA, 3% GLA and 5% GLA group, respectively. 
Hence, the effect of different levels of GLA on brain fatty acids 
composition, along 8 weeks of age (Tables 8, p 77) showed marked effects 
of supplementation on special fatty acids in brain. LA levels were 
significantly decreased to about 0.92%- 1.42% and to 0.76%- 0.92% after 
4 and 8 weeks, respectively in all groups, but with comparatively lower 
levels in omega-6 groups (0.76%- 0.92%). In respect to brain DGLA, 5% 
GLA group showed the significantly highest DGLA level (1.25%) after 8 
weeks. Control group illustrated significant reduction in DGLA (80.5%), 
after 8 weeks compared to that obtained after 4 weeks, but omega-6 
groups showed significantly marked increase (24.2%, 27.4% and 43.2% in 
1%, 3% and 5% GLA groups, respectively) after 8 weeks compared to 
those obtained after 4 weeks. However, high dietary level of GLA (5%) 
resulted in a slight significantly higher level of AA (11.2%) and lower DHA 
level (12.9%) after 8 weeks.  
AA/ LA and AA/ DGLA ratios reflect the changes in AA status in all 
groups. In control group AA/LA and AA/ DGLA ratios were increased by 
about 1.26 and 6.94, respectively fold more than that obtained after 4 
weeks. This can be attributed to the higher levels of EPA (1.07%) after 8 
weeks. On the other hand, while AA/LA ratio was decreasing by about 
8.8% in 1%GLA, it increases by about 87.3% and 72.9% in 3%GLA and 
5%GLA compared to that obtained after 4 weeks, respectively. 
Furthermore, AA/ DGLA was decreased by about 32.4, 29.1 and 45.7% in 
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1%, 3% and 5%GLA groups, respectively compared to that obtained after 
4 weeks. This can be attributed to the effect of EPA in metabolic pathway 
to the formation of AA from DGLA (77, and 85-87). 
The brain DHA level was found to be 6.05% at birth, which 
significantly increased up to 8 weeks. Brain DHA level in 1%GLA group 
was found to be 2.13, 1.07 and 1.08 fold more than that obtained in control 
group, 3%GLA and 5%GLA groups, respectively after 8 weeks. DHA/ EPA 
ratio reflects the changes in DHA status in all groups. After 8 weeks, DHA/ 
EPA was increased by about 93.2% in 1% GLA group, but it decreased by 
about 44.2%, 49.4% and 35.7% in control group, 3% GLA and 5%GLA, 
respectively compared to those obtained after 4 weeks.  
In omega-6 group, rats showed similar profile of fatty acids 
composition, which contains 44.1%- 54% SFA, 23.5%- 26.3% MUFA and 
20.1%- 29.9% PUFA of total fatty acids; and 18%-20.1% as oleic acid 
which represents 70%-76.5% of total MUFA. The higher ratio of n-3/n-6 in 
all groups, after 8 weeks compared to those obtained after 4 weeks, 
observe a normal brain behavior through n-3 status (59). 
 
4.2 Effect of feeding on phospholipids fatty acids composition  
4.2.1 Liver phospholipids fatty acids profile  
In omega-3 group, they were a fall of AA and increase the level of 
DHA in liver PL, whereas the level of ω-3 in cell very important But when 
cell deficient in ω-3 fatty acid has a decrease in DHA and increase levels 
of the end product of ω-6 metabolism, DPA within the sub-cellular 
organelles and mitochondria seem to be more sensitive to a low dietary 
supply as evidenced by the relative abundance of DHA and the changes 
compositions of these organelles in response to dietary deprivation (77, 
88, and 89). The evidence indicates that in early life α-LA precursors are 
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not sufficiently converted to DHA to allow the biochemical and function of 
normal cycle (90). Summed of ω-3 FA after 4 week (Table 9, p 78) 
increased gradually until 8 weeks. On the other hand, in omega-6 group, 
there was a fall in the level of DHA in liver PL during the fourth week 
(Table 10, p 79), whereas the decrease was similar in both 3%GLA and 
5%GLA groups (about 17-18%). At the end of the experiment, all groups 
showed decreases of about 1.36, 1.22 and 1.20 folds than the level at the 
fourth week in the 1% GLA, 3% GLA and 5% GLA groups, respectively. 
Moreover, rats liver PL had higher levels of AA at 28 day, after that the 
levels were decreased in all groups till the end. It was found that the 5% 
GLA group had the highest percentage of AA and DGLA at the end of the 
experiment. AA was increased by about 25% and 11% than both of the 
other groups and it had 2.69 and 2.35 folds more than group 1% GLA and 
3% GLA of DGLA, respectively.  
4.2.2 Plasma phospholipids fatty acids profile  
The fatty acids profiles of plasma phospholipids followed closely the 
degree of supplementation in omega-3 group and illustrate the competitive 
interactions between fatty acid (ω-3 compared with ω-6) metabolic 
pathways (77, 82 and 91). For example, in all groups supplement with a 
constant amount of EPA and AA, fatty acid concentration of AA decreased 
linearly with increasing amounts of DHA supplements. In our results, DHA 
recorded more fold decreases incorporation from plasma into the rat brain 
as well as a reduction in recycling via deacylation/reacylation reactions. 
The overall rate process of DHA uptake from the circulation into the 
brain/retina appears slow and may be rate-limiting for DHA repletion. In 
both of Figures 5 and 6, changes of the plasma phospholipids were shown 
during the experiment especially after 28 days and 56 days of feeding. 
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 All the omega 6 groups showed similar and significant group mean 
reduction in AA concentrations in plasma phospholipids with 
supplementation. After 8 weeks, the reduction in the 5%GLA group was 
about 25% and 44% in both of the 1% GLA and 3% GLA groups, 
respectively coming with the first four weeks. The multiple factors that 
likely account for an actual reduction in AA concentrations include 
competition by EPA and DGLA for esterification into cellular phospholipids 
and the attenuating effect of n-3 fatty acids on ∆5-desaturase, which 
affects the conversion of DGLA to AA (82, 83, 92, and 93). Addition of EPA 
and DHA to formula increased the proportion of LCPs n-3 in plasma 
phospholipids but did not prevent n-6 depletion (82, 88). 
 
 4.2.3 Brain phospholipids fatty acids profile  
 Rat brain phospholipids contained only a small amount of α-LA and 
these results are in agreement with the literature (77, 88). Recycling 
(deacylation and reacyclation) of PUFAs (AA and DHA) in brain 
phospholipids is a going and active process, but unlike α-LA they are much 
susceptible to β-oxidation and thus are conserved in the phospholipids by 
the recycling. Brain phospholipids AA decrease and DHA increase with 
decrease in 18:4n3 and EPA. At the end of experiment, the proportion of 
DHA increased in 1%DHA and 2%DHA group (~79% and ~74%, 
receptively) with similar decrease of EPA (Table 11, p 80). On the other 
hand, in the omega-6 group, there was a parallel in the n-3 and n-6 fatty 
acids in PL compared with the brain FA. Between the 4 and 8 weeks, there 
was found a fall in the level of AA about 26-29% in all groups, related to 
reverse relationship with DGLA. The proportion of DHA was decreased in 
1% GLA group and 3% GLA (~ 13% and ~9%, respectively) at the 28 day 
and (19% and ~20%, receptively) at the end of experiment comparing to 
the level at the fourth week (Table 12, p 81). These data are in agree with 
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that of Wainwright  (94) who noted that feeding with oil containing high 
level of GLA decreased the level of DHA in brain PL by competition 
between the n-6 fatty acid GLA and the n-3 fatty acid DHA. Thus, a long-
sanding question in essential fatty acid research has been whether LCPs 
are accumulated in tissues via metabolism of 18-carbon precursors 
normally abundant in the diet or rather are incorporated directly from 
preformed dietary LCPs. Many previous studies had demonstrated that 
various pathway, either metabolic or involving preformed LCP 
intermediated, are operative for various tissues. What has been total 
lacking in any approach that could assess the quantitative contributions of 
the various known pathways for LCP accumulation? One key aspect of this 
problem is the source of brain DHA because maintenance of its level is 
critical for optimal neutral function. The author chose to hold LA and α-LA 
of the diets constant and change the levels of DHA and GLA at two 
experiments. Rates with omega 3 diets were present were significantly 
related after four weeks. Control rat showed decreased level of DHA 
during 4 weeks. Brain DHA was positively correlated with plasma DHA (r = 
0.82, P< 0.05) and Brain AA was positively correlated with plasma AA (r = 
0.89, P< 0.05). Brain DHA had not related with the increase with DHA in 
diets. We suggested to plasma DHA may be used as a marker of brain 
DHA status. On the other side, rates with omega 6 diets were present 
various metabolic fatty acids pathway, liver and plasma fatty acids were 
significantly related after four weeks, which liver cells are the main site for 
the biosynthesis of LPCs from 18 carbon precursors, and for the formation 
of lipoproteins that transport fatty acids in the plasma and uptake by most 
other cells. Liver DHA was positively correlated with plasma DHA (r = 0.81, 
P< 0.05) and liver AA was positively correlated with plasma AA (r = 0.86, 
P< 0.05). Plasma and liver AA were not correlated with brain AA. However, 
DHA in liver and plasma DHA were significantly associated with DHA in 
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brain (r = 0.81 and 0.92, P< 0.05) and kidney (r = 0.98 and P< 0.05), 
respectively.  
 
4.3. Effect of feeding on tocopherol levels 
It is important to detect antioxidant status, which is very important 
when consumed LCPs in infant fed formulas. Free radical especially 
superoxide (O2•) and other reactive species such as H2O2, are continuously 
produced in vivo. Superoxide in particular is produced by leakage from the 
electron transport chains within the mitochondria system. Risk of oxidative 
damage for premature infant is very important because they are born with 
immature antioxidant status.  
 
4.3.1 Impact of feeding on level of liver tocopherols  
Liver is the major storage organ of α-tocopherol (95). Table 13 
showed that, liver α-tocopherol was decreased by about 10.7-36.6% and 
3-6% and in the omega-3 and omega-6 groups, receptively after 4 weeks 
compared with the level after 2 weeks. Furthermore, liver α- tocopherol in 
the 1% DHA group showed 1.58 fold more than the liver in the 3% DHA 
group after 8 weeks of ages. However it was be found that, 5% GLA group 
had lesser liver α- tocopherol (40.8%) compared with that obtained with 
1%GLA after 8 weeks of age. Our results are in agreement with those of 
other studies which have shown that diets induced high n-3 FA had oils 
lower α- tocopherol content in the rats liver (96) or mice(97). 
 
4.3.2 Impact of feeding on level of plasma tocopherols 
The α-tocopherol level in plasma rapidly raised to about 0.52–11.1 
mg/L in omega-3 group after 4 weeks, while in omega-6 group   was 
increased to about 4.1- 8.82 mg/L at the same period (Table 13, p 81). 
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Continuous decrease in plasma α- tocopherol was noted after 6 weeks in 
both groups and with some differences after 8 weeks. This can be due to 
interaction of omega-3 or omega-6 oils and tocopherol at the gut level, or 
to enhanced post absorptive utilization of tocopherol compared to rats fed 
low level and high level of omega oils.  
 
4.3.3 Impact of feeding on level of brain tocopherols 
Concentration of α-tocopherol in rat’s brain was found to be 12.22 
µg/ total brain at birth. Table 13 showed that, α-tocopherol  significantly 
decrease after 4 weeks and up to 8 weeks in all omega-3 and omega-6 
groups. The consumption of α-tocopherol was lead to %- loss about 29-
40% and 31-38% in the omega-3 and omega-6 groups, respectively after 4 
weeks and loss about 87%- 89% in each after 8 weeks. It was found that, 
the change in brain α–tocopherol being much smaller than that in plasma 
and other tissues, including liver (98-100). Furthermore, the high content of 
PUFA and, more specifically, DHA in rat brain fed omega-3 diet may have 
enhanced the consumption of antioxidants. Gamma-tocopherol was found 
as very small amount in all tissues and plasma. Summary of this section, 
all omega-3 and omega-6 groups, there was trend for α- tocopherol to 
decrease with time, especially between 4 week and 8 weeks of feeding 
with significance difference between the low and high level of ω-3 as well 
as low ω-6 and high concentration.  
 
4.4 Free Radical Activity in brain and liver extracted 
Pervious studies on radical scavenging activity (RSA) have used 
different solvents to dissolve the free radicals in different crude oils (91), 
but were not detected before in brain and liver oil extraction. Hence, the 
results here were difficult to be compared because the reactions were 
done under different conditions. Characteristics of the antioxidant-free 
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radical reactions in the present study were evaluated using total lipids by 
spectrophotometric method with the stable DPPH radical. This method has 
been reported as a simple method for evaluation of the radical scavenging 
activity of a given substance, absorbance at 515 nm decreases as a result 
of a color change from violet to yellow as the radical is scavenged by 
antioxidants through donation of hydrogen to form the stable DPPH-H. So, 
more rapidly of the absorbance decreases, the more potent the antioxidant 
activity of the compounds was in terms of hydrogen donating ability (101). 
Total DPPH radical scavenging capacities of fractions were 
measured and compared in the two groups with different levels of omega-3 
and omega-6. The liver and brain fractions from rat which fed 3% DHA had 
a much weaker radical scavenging activity compared to 2% DHA and 1% 
DHA fed rats firstly at all period of age studied. After 4 weeks of the 
experiment and at a reaction time of 1 min, the liver and brain extract from 
rat 1% DHA and 1% GLA exhibited the strongest activity, and followed by 
the another omega-3 and omega-6 groups as shown in Figure 8a and 8b. 
On the same per weight basis at 4 weeks and after 1 h of incubation, 
26.4% of DPPH radicals were quenched by brain extract from rats fed the 
1% DHA, while brain extract from the 2% DHA and 3% DHA were able to 
quench 33.6% and 53.5%, respectively. Free radicals and radical-
mediated oxidation play roles in many aging-related health problems 
including cancers and heart diseases. To better understand the beneficial 
effects of natural antioxidant in oils, which used in processing infant 
formula or food and differ in their reactions with free radicals, depending on 
biological actions, more experiments should be done. In our present study, 
positive correlation was found between RSA and the levels of tocopherols 
in brain and liver extracted.  
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5.5 Oxidation stability during oven test 
In this part of work, the objectives were to determine the oxidative 
stability of the oils and their formulas for 12 days at 60°C, whereas the 
times of storage was roughly comparable more to 6 months at room 
temperature (20°C), when the general concept of 2 t imes the oxidation 
reaction rate increment with 10°C increment (Q 10 = 2) was applied. On the 
other hand, oil stability is determined under accelerated conditions (60°C 
or more) for several reasons (i) ambient conditions demand an excessively 
long period, (ii) ensure that the starting lipid does not contain high levels of 
oxidation products (e.g. transition metals hexanal, free fatty acids and lipid 
hydroperoxides) and (iii) at high temperatures can contribute to 
decomposition of hydroperoxides, decomposition or volatility of 
antioxidants, and decrease of oxygen solubility rapidly. 
 
5.5.1 Hydroperoxide formation 
5.5.1.1 Peroxide and p-anisidine values 
Peroxide value is used to quantify the hydroperoixdes formed; 
however these are intermediate products in the formation of carbonyl and 
hydroxyl-compound (102). The oils were compared at three different of 
LCPs (1% GLA containing 1% DHA, 3% GLA and 3% DHA) and oils 
extracted from manufactured formulas containing the same fatty acids 
composition. The changes of PV for oils and extracted oils from formulas 
are illustrated in (Figure 9, p 88). PV remained with small changed at a 
very low level (7.1 mmol/kg oil) over 192h in EO 1% GLA (Figure 9), 
whereas the peroxides accumulated in EO 3% DHA to a high level after 
eight days of storage and then decreased, as a result of hydroperoixdes 
Part II Oxidative stability of formula 
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decomposition (102). With respect to control oils (Figure 9), PV sharply 
increase up to 96h and then decreased throughout the rest of the storage 
period, whereas PV was gradual increased by increasing content of LCPs; 
suggested more oxidative problems with these group contained 3%DHA 
compared to the others. To better elucidate degradation of the fat, a p-
anisidine assay was used to determine the aldehyde content of all oils 
(Figure 10, p 89). Like peroxides, p-anisidine values were increased. 
Thereafter, p-anisidine values were decreased, but to a lesser extent than 
PV. Therefore, p-anisidine values, like peroxide values, proved also 
unreliable as indicators of the degree of rancidity for fats exposed to 
extreme oxidative challenge (103). 
 
5.5.2 Ultraviolet absorptivity 
LCPs oxidation can be analyzed by the absorptive increase in the 
UV spectrum (104). During the storage time, lipids that have dienes and 
polienes showed a changed in the double bonds positions, due to 
isomeration and conjugation in the molecule (105). Dienes and trienes 
formation on the oxidation initial steps and they show intense absorption at 
233 and 270 nm, respectively (Figure 12, 13, 14 and 15, p 91-94). 
Absorptive at 233 nm increased gradually with the increase in time, due to 
the formation of conjugated dienes (CD) (Figure 12) during 288h. The CD 
from both oils contained 3% DHA and neutral lipid were increased sharply 
and peaked after 144 h. The sharp increase in the CD might be accounted 
for by the formation of more and more hydroperoxides as primary products 
of oxidation according to structure of non-polar lipid, whereas it is the 
major component of lipid. On the other hand, control with α-tocopherol was 
more stable than the all samples. After 192 h of storage, the CD values 
were decreased, possibly due to the breakdown of unstable 
hydroperoxides. On the another side, CD of EO containing 1% GLA  as 
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well as netural lipid had low change during the storage, from 0 to 288 h, 
indicating a good oxidative stability. Meanwhile, the changes in conjugated 
tienes (CT) were less marked than the changes in CD during the storage 
period. So, increases absorptivity at 270 nm after 6 days of heating being 
as a result of rancid off-flavor compounds formation (aldehydes and 
ketones). Parallel was observed between trends for changes in CD, PV 
and AV.  
The polar fractions extracted from formulas containing 1% emulsifier 
had better OS compared to polar bulk oils fractions at the same induction 
periods (Figure 14 and 15). It is seem to be due to the refining, bleaching 
and deodorization process in which the phospholipids were almost 
completely removed. The incomplete removal of phospholipid, promote the 
initial breakdown of the primary antioxidants. Thus, any subsequent 
storage, due to the lower level of antioxidant, will show a decreased 
stability and a pro-oxidant effect of the PL (106). By comparison, 
phospholipids gained of emulsifiers may be acting by quenching the free 
radicals arising from PUFAs oxidation and thus improving the OS (104). 
Therefore, it could be said that polar fractions added in bulk oils or oils 
used in food industry were mainly responsible for their stabilities (105). 
Ultraviolet scans between 220 and 320 nm after 12 days storage at 60 
were shown in Figure 11. 
 
5.5.2 Hydroperoxide decomposition 
The primary oxidation products for unsaturated fatty acids are the 
hydroperoxides, highly reactive compounds that decompose rapidly, 
yielding a complex mixture of non-volatile and volatile compounds such as 
hydrocarbons, aldehydes and ketones. Aldehydes are practically important 
in stability of infant foods including DHA, which related to flavor alteration 
and quality product (107).We were investigated the decomposition of 
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hydroperoxide as propanal, pentanal, hexanal and nonanal of oils 
prepared from the same amount of LA, α-LA, AA and EPA, but only 
different was the amount of DHA and/or GLA with 150 ppm of α- 
tocopherol. Calibration curves were drawn for the four aldehydes. The 
curves were followed linear relationship with highly significant correlation 
coefficients (R2 better than 0.9 and equal 0.99 for a large number of 
compounds) (Figure 3b, p 84, Table 3b, p 26). 
 
5.5.2.1 Oxidative stability of bulk oils 
Pentanal and hexanal were originated from n-6 fatty acids (LA and 
AA), while the propanal and nonanal were originated from n-3 and n-9 fatty 
acid, respectively. In the control oil, the initial rate of hydroperoxides 
decomposition increased sharply after storage period of 96 h. The low 
propanal, hexanal, pentanal and nonanal values in 1% GLA oil containing 
1% DHA agreed with the corresponding PV obtained for this oil (Figure 9). 
With respect to the high content of n-3 fatty acids in 3%DHA oil was higher 
propanal (33%), lower hexanal (49%) and pentanal (53%), after 192 h than 
those obtained from 3% GLA oil (Figure 16, p 95-102). The lower hexanal 
content without any off-flavor may be due to the addition of coriander oil. 
However, these differences in relative stability may be due to not only to 
fatty acids composition but also to interaction of α-tocopherols as 
antioxidant (108). 
 
5.5.2.2 Stability of extracted oils (EO) 
Oil-in-water emulsions were prepared with oil 10 wt% of the same 
LCPs containing DHA and/or GLA described above and 1% soy lecithin as 
emulsifier in phosphate buffer at pH 3.8. The oxidative stability (OS) of 
these extracted oils were significantly higher during the first 96 h than that 
of the corresponding oils (Figure 16); and this may be resulted from many 
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factors (i) scavenging free radicals by amino acids of protein (109); (ii) 
lecithin may be increasing the contact between the antioxidant and the 
oxidizing fat (103) and/or; (iii) effecting of PC on the decomposition of 
hydroperoxides by catalyze a non-radical pathway (104). Propanal 
analysis was found to be the highest oil after 192 h in 3% DHA oil, while 
the oppositely effect was observed in pentanal formation (Figure 16). On 
the basis of hexanal formation, hexanal did not increase until 96 h of 
storage period, and after 192 h the level was decreased. Decrease of 
hexanal could be as a result of finished fatty acids oxidation, although this 
assertion can not be categorical, because the differences could also be 
ascribed to the manufacturing process  
 
5.5.2.3 Oxidative stability of oil fractions 
 
Bulks oils were sequentially fractionated with chloroform to recover 
NL; followed by acetone to recover GL then methanol to recover PL. 
Numerous studies have been focused on the oxidative stability of emulsion 
containing lecithin. The OS of NL, GL and PL neither is so far nor reported 
in the published literature. Hence, we may have for the first time definitively 
established the OS of oil fractions. The importance of studying oil stability 
fractions is reflected in the utilization of each fraction in the industry. As 
expected in oils, NL (constituted mainly of triacylglycerols) was the major 
fraction followed by GL and PL, respectively (Table 14, p 81). 
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Propanal and hexanal by GC-HS: chromatography of glycolipids of oils (A) 
1%GLA, (B) 3%GLA, (C) 3%DHA and extracted oils (D) EO 1%GLA, (E) EO 
3%GLAand (F) 3%DHA after 96h at 60 ºC. Peaks numbered correspond to 1, 
propanal; 2, pentanal; 3, hexanal; and 4, nonanal. 
 
 
The ratio of saturated to polyunsaturated fatty acids (S/P) in the oil 
fractions is summarized in Table 14. The fractions had a rather similar S/P 
pattern wherein the ratio increased with the increase of the polarity of the 
oil fraction. It was worthy to mention that the S/P ratio recorded the highest 
level in the polar fractions (GL and PL).This may be explanation; the major 
propanal content in polar fractions. On the basis of hexanal formation, in 
the control oil, the rate of hexanal formation increased sharply after 96 h 
(Figure 16), but a different order of stability was observed after 96 to 192 h 
of storage period, detected at the higher level in polar lipids than the 
neutral lipid fraction with increasing in the 3% GLA (Figure 16).Extended 
storage, without daylight, results in high concentrations of propanal and 
hexanal in polar fractions. 
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5.5.2.4 Thiobarbituric acid reactive substances (TBARS) Assay 
A portion of the lipid hydroperoxides that form in the early stages of 
lipid oxidation are broken down to form the low molecular weight volatile 
compound (secondary products) that impart rancidity. Various low 
molecular weight aldehydes, alkanals and nonvolatile precursors of these 
substances react with 2-thiobarbituric acid (TBA), resulting in chromogens 
termed 2-thiobarbituric acid-reactive substances (TBARS) that can be 
determined spectrometric at 532 nm. TBARS values of oils and extracted 
oils (EO) as well as the control are shown in Figure 17. During the test; 
statistical evaluations (p< 0.05) showed that PUFAs significantly affected 
the TBARS values. After the first 2 days of incubation, the lowest values 
were observed for oil containing the lowest level of PUFAs. As the 
accelerated storage period was extend up to 72 h, TBARS values of 3% 
DHA oil increased gradually (Figure17, p 103).  
TBARS of this oil was considerably higher than those of the EO 3% 
DHA over the entire storage period. As explained earlier, removal of 
antioxidant during process is responsible for the compromised stability of 
the modified product. Meanwhile, TBARS values of the EO 1% DHA, as 
such, remained nearly closed with control during the entire storage period, 
indicated its good stability under oven conditions at 60 ºC. The general 
increase in TBARS values of oils during storage time may be due to the 
breakdown of lipid hydroperoxides and the production of secondary 
products (110). Correlations were existed between peroxide value (PV) 
and p-anisidine value (AV) (P <0.05) as well as 2-thiobarbituric acid-
reactive substances (TBARS) and headspace volatiles (propanal) content 
(P<0.001) for most oils and extracted oils. Besides, it was found that a 
negative correlation was demonstrated between the TBRAS formation and 
total phenolic contents.  
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For each of the time periods studies, we measured the ratio of EPA 
and DHA to palmitic acid. These values were used as markers of the lipid 
oxidation progress. We would expect to decreases this ratio with an 
increase in oxidation of EPA and DHA.  
 
5.5.3 Effect of α-tocopherol in bulk oils and extracted oils (EO)    
Lipid oxidation is the most critical parameter affecting in the shelf life 
of the newer food products, which LCPs lipids have been incorporated. 
The many different fatty acids hydroperoxide positional and geometrical 
isomers that are formed during the oxidation of the ω-3 and ω-6 PUFAs up 
on storage rise to a complex mixture of secondary oxidation products. 
Therefore, we was investigated the effect of the conditions of (O/W 
emulsion), pH 3.8, 150 ppm α-tocopherol and temperatures 50°C on the 
oxidative stability in ω-3 and ω-6 enriched formulas and compared with the 
same composition of bulk oils in a storage period (12 days) at 60°C. 
Hydoperoxide formation and decomposition as well as antioxidant activity 
were quantified for oils and finished products in storage. Quality testing of 
several indicators of degradation in new oils enriched in omegas is 
essential to enhancing quality, stability, and nutritional value of these foods 
especially infant formulas.  
The tocopherols are the most important natural antioxidants in fats 
and oils. To understand the mechanism of α-tocopherol as an antioxidant 
compound, it is well known that lipid oxidation started by the abstraction of 
a hydrogen atom from an allylic or bis- allylic position of an USFA (RH) to 
generate an alkyl radical , which combines with molecular oxygen at 
diffusion- controlled rate to produce a lipid peroxyl radical (ROO•). The 
ROO•, having longer lifetimes (ca. 7s) than R• (ca. 10-8 s), propagate the 
oxidation reaction by selectively abstracting hydrogens from RH to form 
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lipid hydroperoxides (ROOH) and another R•  Unsaturated fatty acids have 
different susceptibilities to hydrogen abstraction, depending on the 
dissociation energies of labile C-H bonds within the molecules. C-H bonds 
adjacent to a double bond or at a tertiary carbon atom are weaker and 
easier to break. For the FA series –CH2-(CH= CH- CH2)n- CH2- (n = 1-3), the 
relative oxidation rates increase in the order 1: 40: 80, respectively. It was 
established that the fatty acids oxidizability is much lower for MUSF 
substrates (e.g. oleic acid) than mainly PUFAs. Thus the oxidize ability of 
FA mixture is mainly depended on the number of allylic methlenes therein. 
Thus, the α-tocopherol affected not only the overall formation of volatile 
secondary oxidation products, but also the composition of this group of 
oxidation products (109). In our study, the control oil without antioxidant 
oxidised very rapidly and all the treatments related to hydroperoxide 
formation and decomposition. The inhibition of hydroperoxide 
decomposition by α-tocopherol between the control and sample containing 
α-tocopherol increased with storage time (Table 15, p 82). With 150 ppm of 
α-tocopherol, hexanal and propanal increased after 96 h. The inhibition 
was increased after 144h with decreased in α-tocopherol amount; no 
hexanal detected after this time. Mixture oil with 1% GLA in the presence 
of 150 ppm had a good scavenging peroxyl radicals activity compared with 
others but all oil mixtures had a very low total polyphenols. However; polar 
lipids are found in high levels in EO, strong RSA of these components can 
be expected as well as synergistic activity with α-tocopherol. On the other 
hand, addition of lecithin containing phosphatidylcholine and 
phosphatidyelethanolamine apparentely all facilitate hydrogen or electron 
donation to tocopherols by the amine group. Hence, PL could be extending 
the effectiveness of tocopherols by delaying the irreversible oxidation to 
tocopheryl quinone, thereby delaying the oxidation. As detected, we 
conclusion that these oils in stable up to 144 hour at 60ºC. Additional 
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studies are necessary to show the antioxidant activity between different 
levels of tocopherols and PL, metal ions and poly phenols plus the effect of 
LCPs n-3 on the oxidative and flavour stability of triglycerides remains 
however an open and important question. 
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5 CONCLUSIONS 
Each of the two experiment design contributes some evidence that 
is relevant to possible causal linkages between tissues and plasma 
concentrations of DHA and eicosanoid precussour. The relationship 
between dietary fat and structural fats are very complex. The diet-
induced shifts in the fatty acid composition were greatest in liver, followed 
by brain and then plasma. Plasma DHA can be used as proxies for 
tissues DHA. Accretion liver of LCPs n-6 is more rapid than the LCPs n-3 
series, rendering the latter more dependent upon dietary 
supplementation than the former, while brain accretion is reversible, 
depending on the metabolic pathway. 
 
It would be expected that human infant who received vegetable oil-
based formulas which the essential fatty acids supplied by corn oil, 
sunflower or safflower oil would exhibit a marked decline in brain DHA in 
the first months of life, similar to that observed for the n-3 Def rats in the 
present study.  
 
It could be recommended that higher levels of DHA not contribute 
to increase of DHA in brain, liver or plasma. Whereas addition 1% DHA 
to formula had significant effect in an important time period during four 
weeks, wherein this period is encompasses the majority of rat brain. 
 
In the present study, adding a source of EPA+ DHA to the diet 
concomitant with different amounts of GLA reduced mean AA 
concentration in plasma and increased concentration of EPA. However, 
DGLA increased when the ratio of EPA+DHA to GLA was 1: 0.5, 1: 1.5 or 
1: 2.5. That is may be important to use for infant fed formula with a family 
history of inflammatory or AD diseases. 
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Reduction of plasma AA in the second stage of our experiment 
between 4 weeks and 8 weeks, is very important factor for patients with 
CD or inflammatory condition, such as rheumatoid arthritis, are needed for 
the development of additional treatment strategies of these patients. 
 
Direct evaluation of antioxidants from tissues and plasma 
contributed information to the antioxidant status of an individual. This 
maybe useful for evaluating the risk for degenerative diseases and radical 
scavenging activity could be a good marker for lipid peroxidation. 
 
The OS of NL, GL and PL is neither so far nor reported in the 
published literature. Hence, we may have for the first time definitively 
established the OS of oil fractions. The importance of studying oil stability 
fractions is reflected in the utilization of each fraction in the industry 
especially infant rich PUFAs formulas processing.  
The results of the present investigation indicated that level of LCPs, 
initial PV and the level of polar lipids were significantly affect in the RSA of 
the oils and EO. Beside, α-tocopherol was affected by the overall formation 
of volatile secondary oxidation products.  
In the light of these results, further studies will be required to:  
1. Clarify the effects of long terms administration of DHA oil on lipid 
metabolism and peroxidation.  
2. Molecular and enzymatic studies for consumption a mixtures of 
DHA, EPA plus GLA in some infant or adult inflammatory history 
diseases. 
3. Antioxidant activity between different levels of tocopherols and PL, 
metal ions and polyphenols plus the effect of LCPs n-3 on the 
oxidative and flavour stability of triglycerides remains an open and 
important question. 
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   Table 1: Composition of the two experimental groups and deficient group diets  
    
 
Omega-3 group  
 
Omega-6 group 
 
Ingredient 
 
(g/ 100 g diet) 
 
 
1% DHA 
 
2% DHA 
 
3% DHA 
 
1% GLA 
 
3% GLA 
 
5% GLA 
 
 
 Deficient 
group 
Skim milk 
powder 
20 20 20 20 20 20 20 
Carbohydrate 60 60 60 60 60 60 60 
Sucrose  10 10 10 10 10 10 10 
Malto-dextrin  15 15 15 15 15 15 15 
Cornstarch  15 15 15 15 15 15 15 
Dextrose  20 20 20 20 20 20 20 
Fat 10 10 10 10 10 10 10 
Hydrogenated 
coconut oil 
 
7.12 
 
7.1 
 
7 
 
7.12 
 
6.95 
 
6.87 
 
8.1 
 
Mixed oils 
 
2.88 
 
2.91 
 
3.00 
 
2.87 
 
3.05 
 
3.23 
 
1.9 
Additives: 10 10 10 10 10 10 10 
Cellulose  5 5 5 5 5 5 5 
Salts  3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Vitamins  1 1 1 1 1 1 1 
Choline 
chloride  
0.25 0.25 0.25 0.25 0.25 0.25 0.25 
L-Cystine  0.25 0.25 0.25 0.25 0.25 0.25 0.25 
THBQ* 0.002 0.002 0.002 0.002 0.002 0.002 0.002 
Fatty acids composition 
SFA 69.8 70.9 71.2 69.8 68.7 66.3 75.5 
MFA 10.2 9.8 9.2 10.2 9.5 8.9 14.2 
C18:2n-6 15.24 15.2 15.53 15.19 15.25 15.51 15.96 
C18:3n-3 3.01 2.98 3.11 2.98 3.01 3.04 3.2 
C18:3n-6 0.099 0.098 0.105 0.99 3.01 4.98 nd 
C20:4n-6 0.58 0.55 0.53 0.58 0.59 0.57 nd 
C22:5n-3 0.89 0.89 0.85 0.89 0.87 0.88 nd 
C22:6n-3 0.99 2.01 3.1 0.99 1.01 1.11 
 nd 
n-6 15.92 15.85 16.17 16.76 18.85 21.06 15.96 
n-3 4.89 5.88 7.06 4.86 4.89 5.03 3.2 
n-6/n-3 3.26 2.70 2.29 3.45 3.85 4.19 4.99 
18:2/18:3 5.06 5.10 4.99 5.10 5.07 5.10 4.99 
   * THBQ, t-butylhydroquinone; SFA, total saturated fatty acids; MFA, total  
      monosaturated  fatty acids; nd, not detected 
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     Table 3: Liver fatty acids composition (%) of different levels of DHA during eight weeks*.  
% DHA   Control 1% DHA 2% DHA 3% DHA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 0.57± 0.00 0.25 ± 0.00 0.28 ± 0.00 0.40 ± 0.01 0.64 ± 0.02 0.63 ± 0.05 0.69 ± 0.05 0.46 ± 0.01 0.43 ± 0.05 
C16:0 21.7 ± 0.21 25.2 ± 0.21 25.6 ± 0.11 20.4 ± 0.25 22.4 ± 0.74 21.2 ± 0.45 23.3 ± 0.55 21.3 ± 0.35 23.6 ± 0.23 
C16:1n-7 1.06 ± 0.00 0.23 ± 0.00 0.28 ± 0.02 1.86 ± 0.12 3.91 ± 0.09 1.83 ± 0.17 3.31 ± 0.60 1.40 ± 0.14 1.31 ± 0.07 
C18:0 19.9 ± 0.17 11.3 ± 0.05 12.5 ± 0.09 16.5 ± 0.36 16.1 ± 0.26 15.6 ± 0.35 15.4 ± 0.27 16.0 ± 0.45 15.6 ± 0.23 
C18:1n-9 10.8 ± 0.08 19.5 ± 0.10 19.2 ± 0.12 12.0 ± 0.25 10.9 ± 0.14 13.1 ± 0.27 8.24 ± 0.11 10.2 ± 0.15 9.21 ± 0.12 
C18:1n-7 2.02 ± 0.04 3.20 ± 0.05 3.10 ± 0.03 2.01 ± 0.04 4.59 ± 0.07 2.52 ± 0.09 3.89 ± 0.02 2.01 ± 0.07 1.31 ± 0.04 
C18:2n-6 11.9 ± 0.12 12.3 ± 0.16 13.8 ± 0.13 13.3 ± 0.06 11.6 ± 0.11 15.3 ± 0.21 14.4 ± 0.45 14.0 ± 0.23 16.2 ± 0.14 
C18:3n-6 0.61 ± 0.02 0.06 ± 0.00 0.04 ± 0.00 0.43 ± 0.00 0.21 ± 0.00 0.25 ± 0.00 0.22 ± 0.05 0.19 ± 0.02 0.18 ± 0.00 
C20:0 0.16 ± 0.00 nd nd 0.44 ± 0.01 0.19 ± 0.01 0.92 ± 0.05 0.12 ± 0.00 0.59 ± 0.01 0.33 ± 0.00 
C18.3n-3 0.12 ± 0.00 0.45 ± 0.04 0.52 ± 0.01 nd 0.05 ± 0.00 nd 0.04 ± 0.00 nd 0.08 ± 0.00 
C18:4n-3 nd nd nd 0.23 ± 0.02 0.29 ± 0.00 0.35 ± 0.00 0.41 ± 0.03 0.86 ± 0.04 0.46 ± 0.01 
C20:3n-6 0.91 ± 0.05 0.06 ± 0.00 0.04 ± 0.00 0.84 ± 0.03 1.50 ± 0.03 1.21 ± 0.14 1.58 ± 0.05 1.28 ± 0.07 1.46 ± 0.04 
C22:0 0.31 ± 0.00 nd nd nd 0.19 ± 0.00 0.73 ± 0.05 nd 0.24 ± 0.00 0.04 ± 0.00 
C20:4n-6 19.8 ± 0.23 14.1 ± 0.12 16.9 ± 0.07 17.6 ± 0.15 10.5 ± 0.20 12.1 ± 0.39 9.88 ± 0.38 11.3 ± 0.24 9.72 ± 0.11 
C22:1n-9 nd nd nd 0.13 ± 0.00 nd 0.10 ± 0.00 nd 0.29 ± 0.00 0.27 ± 0.00 
C20:5n-3 0.31 ± 0.02 0.49 ± 0.02 0.45 ± 0.03 1.5 ± 0.05 0.76 ± 0.01 1.75 ± 0.16 1.39 ± 0.09 5.52 ± 0.04 2.19 ± 0.02 
C24:0 2.33 ± 0.02 3.68 ± 0.01 0.24 ± 0.00 0.66 ± 0.00 0.64 ± 0.06 0.39 ± 0.02 1.13 ± 0.04 0.53 ± 0.00 0.65 ± 0.01 
C24:1 nd 2.45 ± 0.01 0.12 ± 0.00 0.21 ± 0.00 0.21 ± 0.00 0.15 ± 0.00 0.09 ± 0.00 0.42 ± 0.01 0.32 ± 0.00 
C22:5n-3 1.49 ± 0.09 1.63 ±  0.02 0.75 ± 0.02 1.77 ± 0.12 1.39 ± 0.16 1.86 ± 0.09 1.60 ± 0.10 2.97 ± 0.12 1.82 ± 0.14 
C22:6n-3 5.86 ± 0.11 4.93 ± 0.04 6.03 ± 0.05 9.41 ± 0.28 13.9 ± 0.52 9.91 ± 0.89 14.3 ± 0.33 9.98 ± 0.24 14.8 ± 0.19 
∑ SFA§ 42.7 ± 0.35 40.43 ± 0.35 38.6 ± 0.28 38.4 ± 0.41 40.2 ± 0.67 39.5 ± 0.55 40.6 ± 0.64 39.1 ± 0.48 40.7 ± 0.41 
∑ MUFA# 14.2 ± 0.12 25.38 ± 0.15 22.7 ± 0.12 16.2 ± 0.21 19.6 ± 0.12 19.6 ± 0.32 15.5 ± 0.23 14.3 ± 0.28 12.4 ± 0.14 
∑ PUFA$ 43.1 ± 0.42 34.02 ± 0.35 38.6 ± 0.29 45.1 ± 0.33 40.5 ± 0.49 42.7 ± 0.95 43.8 ± 0.45 46.1 ± 0.35 46.9 ± 0.25 
n-3/n-6 0.29 0.28 0.25 0.4 0.69 0.48 0.68 0.72 0.7 
AA/LA 1.66 1.15 1.23 1.32 0.91 0.79 0.69 0.81 0.6 
AA/DGLA 21.79 235 423.25 20.95 7 10 6.25 8.83 6.66 
EPA/AA 0.12 0.03 0.03 0.09 0.07 0.14 0.14 0.49 0.23 
DHA/EPA 2.52 10.06 13.4 6.27 18.29 5.66 10.29 1.81 6.76 
PI** 164.70 122.63 138.73 182.47 182.87 169.4 191.97 196.72 203.13 
    *Each parameter is present as the mean form three rat ± SD; SFA: Total saturated fatty acids; MUFA: total monounsaturated fatty acids; PUFA: total polyunsaturated fatty  
       acids; LA: linoleic acid; DGLA: dihomogamma-linolenic acid; AA: arachidonic acid; EPA: eicosapentanoic acid and DHA: docosahexanoic  acid. nd, not detected 
 ** PI: Peroxidizability index (sum of percentages of individual fatty acids х number of active methylenes). 
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     Table 4: Liver fatty acids composition (%) of different levels of GLA during eight weeks** 
% GLA   Control 1% GLA 3% GLA  5% GLA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 0.57± 0.00 0.25 ± 0.00 0.28 ± 0.00 0.40 ± 0.01 0.64 ± 0.02 0.40 ± 0.05 0.42 ± 0.00 0.49 ± 0.01 0.51 ± 0.05 
C16:0 21.7 ± 0.21 25.2 ± 0.21 25.6 ± 0.11 20.4 ± 0.18 22.5 ± 0.23 19.3 ± 0.32 22.0 ± 0.11 19.3 ± 0.21 23.6 ± 0.35 
C16:1n-7 1.06 ± 0.00 0.23 ± 0.00 0.28 ± 0.02 1.86 ± 0.00 3.50 ± 0.06 1.35 ± 0.05 1.40 ± 0.02 1.64 ± 0.04 2.11 ± 0.11 
C18:0 19.9 ± 0.17 11.3 ± 0.05 12.5 ± 0.09 16.5 ± 0.12 16.1 ± 0.18 17.6 ± 0.29 18.2 ± 0.14 17.2 ± 0.16 18.9 ± 0.21 
C18:1n-9 10.8 ± 0.08 19.5 ± 0.10 19.2 ± 0.12 12.0 ± 0.08 11.9± 0.21 9.20 ± 0.18 9.05 ± 0.11 9.82 ± 0.18 10.77 ± 0.14 
C18:1n-7 2.02 ± 0.04 3.20 ± 0.05 3.10 ± 0.03 1.97 ± 0.02 4.59 ± 0.04 2.10 ± 0.04 2.10 ± 0.02 1.78 ± 0.12 2.13 ± 0.01 
C18:2n-6 11.9 ± 0.12 12.3 ± 0.16 13.8 ± 0.13 13.3 ± 0.09 11.6 ± 0.07 12.3 ± 0.10 12.7 ± 0.16 12.5 ± 0.14 11.6 ± 0.18 
C18:3n-6 0.61 ± 0.02 0.06 ± 0.00 0.04 ± 0.00 0.43 ± 0.02 0.21 ± 0.00 0.98 ± 0.04 0.31 ± 0.01 1.10 ± 0.00 0.40 ± 0.01 
C20:0 0.16 ± 0.00 nd nd 0.44 ± 0.01 0.19 ± 0.00 0.17 ± 0.00 0.12 ± 0.00 0.37 ± 0.01 0.18 ± 0.00 
C18.3n-3 0.12 ± 0.00 0.45 ± 0.04 0.52 ± 0.01 0.03 ± 0.00 0.05 ± 0.00 0.07 ± 0.00 0.06 ± 0.00 0.03 ± 0.00 0.05 ± 0.00 
C18:4n-3 nd nd nd 0.23 ± 0.00 0.29 ± 0.04 0.30 ± 0.01 0.23 ± 0.03 0.47 ± 0.01 0.27 ± 0.00 
C20:3n-6 0.91 ± 0.05 0.06 ± 0.00 0.04 ± 0.00 0.84 ± 0.03 1.5 ± 0.11 1.10 ± 0.03 1.47 ± 0.08 1.17 ± 0.01 1.42 ± 0.07 
C22:0 0.31 ± 0.00 nd nd nd 0.19 ± 0.02 nd 0.15 ± 0.00 nd 0.16 ± 0.00 
C20:4n-6 19.8 ± 0.23 14.1 ± 0.12 16.9 ± 0.07 18.1 ± 0.23 15.6 ± 0.32 25.9 ± 0.45 24.1 ± 0.32 24.9 ± 0.25 9.72 ± 0.11 
C22:1n-9 nd nd nd 0.13 ± 0.00 nd nd nd 0.07 ± 0.00 0.27 ± 0.00 
C20:5n-3 0.31 ± 0.02 0.49 ± 0.02 0.45 ± 0.03 1.50 ± 0.01 0.76 ± 0.04 0.28 ± 0.00 0.25 ± 0.04 0.45 ± 0.01 2.19 ± 0.02 
C24:0 2.33 ± 0.02 3.68 ± 0.01 0.24 ± 0.00 0.66 ± 0.01 0.64 ± 0.06 0.90 ± 0.12 0.52 ± 0.11 1.39 ± 0.04 0.85 ± 0.04 
C24:1 nd 2.45 ± 0.01 0.12 ± 0.00 nd nd 0.30 ± 0.01 0.36 ± 0.04 0.03 ± 0.00 0.26 ± 0.02 
C22:5n-3 1.49 ± 0.09 1.63 ±  0.02 0.75 ± 0.02 1.77 ± 0.04 1.39 ± 0.04 1.72 ± 0.01 1.14 ± 0.09 1.35 ± 0.04 0.93 ± 0.07 
C22:6n-3 5.86 ± 0.11 4.93 ± 0.04 6.03 ± 0.05 9.41 ± 0.13 8.13 ± 0.24 5.96 ± 0.11 5.43 ± 0.17 5.59 ± 0.08 4.33 ± 0.21 
SFA 42.7 ± 0.35 40.43 ± 0.35 38.6 ± 0.28 38.4 ± 0.28 40.3 ± 0.41 38.3 ± 0.61 41.4 ± 0.35 38.8 ± 0.37 44.2 ± 0.54 
MUFA 14.2 ± 0.12 25.38 ± 0.15 22.7 ± 0.12 16.0 ± 0.07 20.0 ± 0.28 13.0 ± 0.21 12.9 ± 0.15 13.6 ± 0.35 15.3 ± 0.24 
PUFA 43.1 ± 0.42 34.02 ± 0.35 38.6 ± 0.29 45.6 ± 0.35 39.5 ± 0.74 48.6 ± 0.58 45.7 ± 0.68 47.6 ± 0.55 40.5 ± 0.68 
n-3/n-6 0.29 0.28 0.25 0.4 0.37 0.21 0.18 0.20 0.17 
AA/LA 1.66 1.15 1.23 1.36 1.34 2.11 1.89 2.00 1.82 
AA/DGLA 21.79 235 423.25 21.6 10.4 23.5 16.4 21.3 14.9 
EPA/AA 0.12 0.03 0.03 0.08 0.05 0.01 0.01 0.02 0.02 
DHA/EPA 2.52 10.06 13.4 6.27 10.70 21.29 21.72 12.42 12.72 
PI 164.70 122.63 138.73 184.6 157.1 181.4 165.6 174.6 143.7 
  ** Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
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     Table 5: Plasma fatty acids composition (%) of different levels of DHA during eight weeks** 
% DHA   Control 1% DHA 2% DHA 3% DHA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 1.41± 0.00 0.43 ± 0.00 0.38 ± 0.00 1.05 ± 0.03 1.36 ± 0.09 1.72 ± 0.02 1.92 ± 0.01 1.88 ± 0.02 1.56 ± 0.02 
C16:0 28.7 ± 0.10 30.1 ± 0.14 31.1 ± 0.11 23.8 ± 0.15 26.3 ± 0.19 25.2 ± 0.25 26.8 ± 0.36 23.9 ± 0.16 24.7 ± 0.17 
C16:1n-7 1.64 ± 0.00 0.52 ± 0.00 0.58 ± 0.02 0.53 ± 0.01 1.58 ± 0.02 1.74 ± 0.08 1.77 ± 0.02 1.32 ± 0.05 1.84 ± 0.04 
C18:0 8.38 ± 0.07 12.5 ± 0.06 12.7 ± 0.09 12.1 ± 0.09 12.4 ± 0.06 8.91 ± 0.14 10.1 ± 0.15 10.3 ± 0.28 11.8 ± 0.19 
C18:1n-9 17.5 ± 0.08 14.1 ± 0.11 15.2 ± 0.12 15.4 ± 0.14 16.4 ± 0.17 18.4 ± 0.21 18.8 ± 0.25 19.0 ± 0.06 19.3 ± 0.26 
C18:1n-7 1.62 ± 0.04 nd nd 1.94 ± 0.04 1.91 ± 0.09 1.16 ± 0.05 1.45 ± 0.06 1.69 ± 0.07 1.78 ± 0.09 
C18:2n-6 21.1 ± 0.11 16.4 ± 0.16 9.70 ± 0.13 14.5 ± 0.28 14.3 ± 0.19 18.0 ± 0.24 17.1 ± 0.19 21.9 ± 0.29 21.1 ± 0.19 
C18:3n-6 1.23 ± 0.02 0.11 ± 0.00 0.06 ± 0.00 0.20 ± 0.00 0.66 ± 0.00 0.39 ± 0.04 0.76 ± 0.04 0.27 ± 0.01 0.88 ± 0.03 
C20:0 0.42 ± 0.00 nd nd 0.32 ± 0.00 0.43 ± 0.03 0.34 ± 0.01 0.47 ± 0.01 0.35 ± 0.08 0.42 ± 0.02 
C18.3n-3 1.26 ± 0.00 0.64 ± 0.04 0.54 ± 0.01 6.05 ± 0.11 4.41 ± 0.09 2.67 ± 0.09 2.64 ± 0.06 2.78 ± 0.07 1.56 ± 0.01 
C18:4n-3 nd 0.28 ± 0.00 nd 1.69 ± 0.09 1.02 ± 0.11 1.56 ± 0.06 1.36 ± 0.05 1.59 ± 0.03 1.14 ± 0.04 
C20:3n-6 0.73 ± 0.05 0.03 ± 0.00 0.02 ± 0.00 0.54 ± 0.00 0.54 ± 0.04 0.98 ± 0.04 0.78 ± 0.03 0.59 ± 0.02 0.85 ± 0.02 
C22:0 0.63 ± 0.01 nd nd 0.36 ± 0.00 0.31 ± 0.01 0.35 ± 0.01 0.34 ± 0.01 0.27 ± 0.01 0.35 ± 0.01 
C20:4n-6 8.89 ± 0.09 18.1 ± 0.12 24.2 ± 0.07 14.3 ± 0.35 8.93 ± 0.28 10.7 ± 0.35 7.04 ± 0.38 7.16 ± 0.29 4.37 ± 0.19 
C22:1n-9 nd nd nd 0.38 ± 0.01 0.30 ± 0.02 0.63 ± 0.05 0.45 ± 0.04 0.21 ± 0.02 0.22 ± 0.01 
C20:5n-3 3.08 ± 0.02 2.5 ± 0.02 0.48 ± 0.03 1.63 ± 0.04 1.04 ± 0.01 2.15 ± 0.07 1.57 ± 0.15 2.58 ± 0.05 2.09 ± 0.08 
C24:0 0.24 ± 0.02 0.18 ± 0.01 0.21 ± 0.00 0.53 ± 0.01 0.63 ± 0.08 0.64 ± 0.01 0.67 ± 0.03 0.66 ± 0.08 0.59 ± 0.07 
C24:1 nd nd nd nd nd nd nd nd nd 
C22:5n-3 0.61 ± 0.09 0.60 ±  0.02 0.15 ± 0.02 0.85 ± 0.02 0.47 ± 0.01 0.79 ± 0.03 0.42 ± 0.01 0.71 ± 0.04 0.45 ± 0.08 
C22:6n-3 2.02 ± 0.11 3.50 ± 0.04 4.50 ± 0.05 3.26 ± 0.18 6.95 ± 0.48 3.58 ± 0.36 5.53 ± 0.29 2.77 ± 0.13 4.85 ± 0.19 
SFA 39.5 ± 0.18 43.2 ± 0.18 44.4 ± 0.18 38.2 ± 0.18 41.4 ± 0.28 37.2 ± 0.35 40.3 ± 0.45 37.4 ± 0.35 39.4 ± 0.28 
MUFA 23.8 ± 0.11 14.6 ± 0.12 15.8 ± 0.09 18.3 ± 0.13 20.2 ± 0.21 21.9 ± 0.28 22.5 ± 0.28 22.2 ± 0.18 23.1 ± 0.29 
PUFA 36.3 ± 0.25 42.1 ± 0.28 39.8 ± 0.23 43.9 ± 0.58 38.3 ± 0.94 40.9 ± 0.95 37.2 ± 0.65 40.4 ± 0.55 37.3 ± 0.59 
n-3/n-6 0.14 0.22 0.17 0.46 0.57 0.36 0.45 0.35 0.37 
AA/LA 0.42 1.11 2.49 0.99 0.62 0.60 0.41 0.33 0.21 
AA/DGLA 12.18 603.33 1210.0 26.56 16.54 10.99 9.03 12.14 5.14 
EPA/AA 0.05 0.14 0.02 0.11 0.12 0.20 0.22 0.36 0.48 
DHA/EPA 4.70 1.40 9.38 2.00 6.68 1.67 3.52 1.07 2.32 
PI 86.10 138.40 148.39 133.62 130.48 122.23 115.80 106.64 104.34 
  ** Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
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     Table 6: Plasma fatty acids composition (%) of different levels of GLA during eight weeks** 
% GLA   Control 1% GLA 3% GLA 5% GLA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 1.41± 0.00 0.43 ± 0.00 0.38 ± 0.00 1.05 ± 0.03 1.26 ± 0.09 1.22 ± 0.02 1.28 ± 0.01 1.18 ± 0.02 1.24 ± 0.02 
C16:0 28.7 ± 0.10 30.1 ± 0.14 31.1 ± 0.11 24.5 ± 0.18 25.6 ± 0.24 24.1 ± 0.23 26.7 ± 0.29 23.2 ± 0.23 27.0 ± 0.35 
C16:1n-7 1.64 ± 0.00 0.52 ± 0.00 0.58 ± 0.02 1.53 ± 0.01 2.95 ± 0.01 1.01 ± 0.01 1.90 ± 0.07 1.91 ± 0.04 2.69 ± 0.02 
C18:0 8.38 ± 0.07 12.5 ± 0.06 12.7 ± 0.09 10.1 ± 0.11 11.0 ± 0.14 11.2 ± 0.14 11.5 ± 0.24 11.7 ± 0.18 11.5 ± 0.17 
C18:1n-9 17.5 ± 0.08 14.1 ± 0.11 15.2 ± 0.12 15.6 ± 0.12 14.4 ± 0.21 13.2 ± 0.08 14.4 ± 0.29 13.0 ± 0.12 15.0 ± 0.21 
C18:1n-7 1.62 ± 0.04 nd nd 1.94 ± 0.04 2.91 ± 0.05 1.85 ± 0.04 2.55 ± 0.05 1.76 ± 0.01 2.35 ± 0.04 
C18:2n-6 21.1 ± 0.11 16.4 ± 0.16 9.70 ± 0.13 14.3 ± 0.21 20.2 ± 0.21 15.5 ± 0.09 19.3 ± 0.32 16.5 ± 0.18 19.5 ± 0.32 
C18:3n-6 1.23 ± 0.02 0.11 ± 0.00 0.06 ± 0.00 0.25 ± 0.00 0.23 ± 0.00 1.62 ± 0.04 1.40 ± 0.04 1.70 ± 0.04 1.30 ± 0.07 
C20:0 0.42 ± 0.00 nd nd 0.32 ± 0.01 0.43 ± 0.01 0.32 ± 0.00 0.14 ± 0.00 0.33 ± 0.00 0.20 ± 0.00 
C18.3n-3 1.26 ± 0.00 0.64 ± 0.04 0.54 ± 0.01 6.05 ± 0.17 1.41 ± 0.04 6.51 ± 0.21 1.18 ± 0.11 6.91 ± 0.15 1.19 ± 0.02 
C18:4n-3 nd 0.28 ± 0.00 nd 1.89 ± 0.03 1.02 ± 0.02 0.43 ± 0.02 0.99 ± 0.08 0.90 ± 0.01 0.81 ± 0.01 
C20:3n-6 0.73 ± 0.05 0.03 ± 0.00 0.02 ± 0.00 0.54 ± 0.02 0.84 ± 0.01 0.46 ± 0.04 1.01 ± 0.01 0.37 ± 0.04 0.89 ± 0.03 
C22:0 0.63 ± 0.01 nd nd 0.16 ± 0.00 0.11 ± 0.00 0.43 ± 0.00 0.10 ± 0.00 0.17 ± 0.00 0.21 ± 0.00 
C20:4n-6 8.89 ± 0.09 18.1 ± 0.12 24.2 ± 0.07 14.3 ± 0.07 12.2 ± 0.21 13.6 ± 0.21 13.4 ± 0.35 13.8 ± 0.21 13.5 ± 0.17 
C22:1n-9 nd nd nd 0.08 ± 0.00 0.03 ± 0.00 0.20 ± 0.00 0.14 ± 0.00 0.24 ± 0.00 0.12 ± 0.00 
C20:5n-3 3.08 ± 0.02 2.5 ± 0.02 0.48 ± 0.03 1.63 ± 0.02 1.18 ± 0.02 5.28 ± 0.11 2.14 ± 0.07 3.07 ± 0.02 2.01 ± 0.09 
C24:0 0.24 ± 0.02 0.18 ± 0.01 0.21 ± 0.00 1.01 ± 0.02 0.63 ± 0.01 0.85 ± 0.04 0.60 ± 0.02 0.85 ± 0.11 0.78 ± 0.04 
C24:1 nd nd nd nd nd nd nd nd nd 
C22:5n-3 0.61 ± 0.09 0.60 ±  0.02 0.15 ± 0.02 0.55 ± 0.04 0.47 ± 0.00 0.43 ± 0.01 0.25 ± 0.01 0.61 ± 0.04 0.35 ± 0.00 
C22:6n-3 2.02 ± 0.11 3.50 ± 0.04 4.50 ± 0.05 4.06 ± 0.10 3.05 ± 0.04 1.64 ± 0.42 1.04 ± 0.01 1.82 ± 0.05 1.01 ± 0.08 
SFA 39.5 ± 0.18 43.2 ± 0.18 44.4 ± 0.18 37.2 ± 0.16 39.0 ± 0.40 38.1 ± 0.12 40.4 ± 0.52 37.4 ± 0.16 40.9 ± 0.54 
MUFA 23.8 ± 0.11 14.6 ± 0.12 15.8 ± 0.09 19.2 ± 0.48 20.3 ± 0.27 16.2 ± 0.51 18.9 ± 0.39 16.9 ± 0.19 18.75 ± 0.23 
PUFA 36.3 ± 0.25 42.1 ± 0.28 39.8 ± 0.23 43.5 ± 0.18 40.6 ± 0.54 45.5 ± 0.23 40.7 ± 0.94 45.6 ± 0.37 40.4 ± 0.74 
n-3/n-6 0.14 0.22 0.17 0.48 0.21 0.46 0.16 0.41 0.15 
AA/LA 0.42 1.11 2.49 1.00 0.60 0.88 0.70 0.83 0.70 
AA/DGLA 12.18 603.33 1210.0 26.39 14.52 29.70 13.28 37.19 15.21 
EPA/AA 0.05 0.14 0.02 0.11 0.10 0.39 0.16 0.22 0.15 
DHA/EPA 4.70 1.40 9.38 2.49 2.58 0.31 0.49 0.59 0.40 
PI 86.10 138.40 148.39 138.5 112.8 136.8 107.2 130.2 104.7 
  ** Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
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    Table 7: Brain fatty acids composition (%) of different levels of DHA during eight weeks**.  
% DHA  Control 1% DHA 2% DHA 3% DHA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 0.87 ± 0.00 1.40 ± 0.00 1.60 ± 0.01 0.24 ± 0.00 0.41 ± 0.02 0.21 ± 0.01 0.34 ± 0.02 0.52 ± 0.03 0.4 ± 0.01 
C16:0 25.3 ± 0.11 26.8 ± 0.12 26.4 ± 0.14 21.2 ± 0.15 21.6 ± 0.12 21.8 ± 0.11 22.4 ± 0.16 23.1 ± 0.15 22.1± 0.15 
C16:1n-7 1.46 ± 0.01 1.15 ± 0.01 1.24 ± 0.03 0.47 ± 0.01 0.47 ± 0.03 0.45 ± 0.00 0.41 ± 0.01 0.6 ± 0.05 0.4 ± 0.02 
C18:0 18.8 ± 0.12 21.7 ± 0.05 22.1 ± 0.08 20.2 ± 0.31 21.5 ± 0.25 21.7 ± 0.14 22.1 ± 0.18 21.7 ± 0.12 20.9 ± 0.15 
C18:1n-9 19.5 ± 0.04 18.0 ± 0.07 18.4 ± 0.04 19.5 ± 0.25 19.1 ± 0.08 18.4 ± 0.23 18.0 ± 0.35 18.7 ± 0.28 18.2 ± 0.23 
C18:1n-7 2.82 ± 0.01 4.98 ± 0.03 3.50 ± 0.01 4.26 ± 0.03 4.01 ± 0.01 4.4 ± 0.1 4.01 ± 0.01 4.3 ± 0.15 4.01 ± 0.02 
C18:2n-6 8.51 ± 0.02 1.42 ± 0.00 1.53 ± 0.02 0.94 ± 0.01 0.97 ± 0.05 0.93 ± 0.02 0.8 ± 0.02 1.12 ± 0.05 0.95 ± 0.02 
C18:3n-6 0.15 ± 0.00 1.04 ± 0.00 0.11 ± 0.00 0.07 ± 0.00 nd 0.05 ± 0.00 0.1 ± 0.01 0.85 ± 0.04 0.11 ± 0.01 
C20:0 0.15 ± 0.00 0.12 ± 0.00 0.30 ± 0.00 0.07 ± 0.00 nd 0.03 ± 0.00 nd 0.16 ± 0.00 nd 
C18.3n-3 0.15 ± 0.00 0.06 ± 0.00 0.41 ± 0.00 0.49 ± 0.02 0.52 ± 0.00 0.5 ± 0.01 0.41 ± 0.02 0.46 ± 0.01 0.44 ± 0.01 
C18:4n-3 nd 0.75 ± 0.01 0.78 ± 0.01 1.61 ± 0.03 1.82 ± 0.01 1.36 ± 0.02 1.89 ± 0.05 1.74 ± 0.21 1.72 ± 0.04 
C20:3n-6 1.01 ± 0.01 1.28 ± 0.04 0.25 ± 0.00 0.69 ± 0.01 0.91 ± 0.06 0.53 ± 0.00 1.1 ± 0.02 0.65 ± 0.02 1.53 ± 0.05 
C22:0 0.14 ± 0.00 0.42 ± 0.00 0.45 ± 0.01 0.47 ± 0.02 0.52 ± 0.01 0.55 ± 0.00 0.5 ± 0.01 0.48 ± 0.02 0.69 ± 0.02 
C20:4n-6 12.9 ± 0.15 9.74 ± 0.08 13.2 ± 0.13 11.8 ± 0.15 10.5 ± 0.23 11.3 ± 0.14 9.69 ± 0.24 9.93 ± 0.25 9.01 ± 0.21 
C22:1n-9 nd 0.12 ± 0.00 0.05 ± 0.00 0.4 ± 0.01 0.19 ± 0.01 0.31 ± 0.00 0.29 ± 0.01 0.35 ± 0.01 0.71 ± 0.02 
C20:5n-3 0.24 ± 0.00 0.49 ± 0.00 1.07 ± 0.03 0.49 ± 0.01 0.45 ± 0.00 0.49 ± 0.03 1.07 ± 0.04 0.44 ± 0.01 1.78 ± 0.06 
C24:0 1.68 ± 0.01 3.56 ± 0.02 1.45 ± 0.03 2.82 ± 0.02 1.85 ± 0.04 2.42 ± 0.01 1.55 ± 0.03 1.65 ± 0.02 1.71 ± 0.03 
C24:1 nd 1.46 ± 0.01 0.35 ± 0.00 0.59 ± 0.00 0.96 ± 0.01 0.96 ± 0.01 0.63 ± 0.01 0.24 ± 0.01 0.6 ± 0.01 
C22:5n-3 0.23 ± 0.00 0.25 ± 0.00 0.23 ± 0.00 0.32 ± 0.02 0.25 ± 0.00 0.3 ± 0.00 0.25 ± 0.02 0.43 ± 0.01 0.65 ± 0.02 
C22:6n-3 6.05 ± 0.05 5.10 ± 0.07 6.55 ± 0.03 13.2 ± 0.11 13.9 ± 0.08 13.3 ± 0.11 14.4 ± 0.41 12.6 ± 0.53 14.0 ± 0.24 
∑ SFA§ 45.3 ±  0.22 54.0 ± 0.18 52.3 ± 0.21 45.0 ± 0.23 45.9 ± 0.19 46.7 ± 0.16 46.9 ± 0.19 47.3 ± 0.11 45.8 ± 0.12 
∑ MUFA# 24.0 ± 0.04 25.7 ± 0.09 23.5 ± 0.03 25.2 ± 0.18 24.7 ± 0.23 24.5 ± 0.23 23.4 ± 0.34 24.2 ± 0.12 23.9 ± 0.15 
∑ PUFA$ 30.7 ± 0.19 20.1 ± 0.10 24.1 ± 0.21 29.6 ± 0.14 29.3 ± 0.28 28.8 ± 0.12 29.7 ± 0.48 28.4 ± 0.38 29.9 ± 0.31 
n-3/n-6 0.36 0.49 0.60 1.19 1.37 1.25 1.54 1.27 1.58 
AA/LA 1.52 6.86 8.63 12.55 10.82 12.15 12.11 8.87 9.48 
AA/DGLA 12.77 7.61 52.80 17.10 11.54 21.32 8.81 15.28 5.89 
EPA/AA 0.13 0.05 0.08 0.04 0.04 0.04 0.11 0.04 0.20 
DHA/EPA 3.60 10.41 6.12 26.94 30.89 27.14 13.46 28.64 7.87 
PI* 123.19 94.02 119.78 168.17 169.13 165.48 174.04 159.66 173.89 
    ** Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
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    Table 8: Brain fatty acids composition (%) of different levels of GLA during eight weeks** 
% GLA   Control 1% GLA 3% GLA 5% GLA 
Weeks At birth 4 8 4 8 4 8 4 8 
C14:0 0.87 ± 0.00 1.40 ± 0.00 1.60 ± 0.01 0.24 ± 0.00 0.41 ± 0.02 0.32 ± 0.01 0.13 ± 0.02 0.30 ± 0.03 0.13 ± 0.01 
C16:0 25.3 ± 0.11 26.8 ± 0.12 26.4 ± 0.14 21.2 ± 0.32 20.3 ± 0.24 21.1 ± 0.23 21.2 ± 0.18 21.4 ± 0.12 20.1 ± 0.32 
C16:1n-7 1.46 ± 0.01 1.15 ± 0.01 1.24 ± 0.03 0.47 ± 0.01 0.47 ± 0.01 0.61 ± 0.01 0.45 ± 0.05 0.46 ± 0.01 0.38 ± 0.01 
C18:0 18.8 ± 0.12 21.7 ± 0.05 22.1 ± 0.08 20.2 ± 0.12 21.3 ± 0.21 21.4 ± 0.29 21.7 ± 0.24 19.9 ± 0.14 21.9 ± 0.21 
C18:1n-9 19.5 ± 0.04 18.0 ± 0.07 18.4 ± 0.04 19.5 ± 0.11 20.1 ± 0.14 18.9 ± 0.24 19.4 ± 0.32 19.2 ± 0.12 18.5 ± 0.25 
C18:1n-7 2.82 ± 0.01 4.98 ± 0.03 3.50 ± 0.01 4.33 ± 0.09 4.58 ± 0.09 4.29 ± 0.11 4.58 ± 0.17 4.32 ± 0.09 4.08 ± 0.17 
C18:2n-6 8.51 ± 0.02 1.42 ± 0.00 1.53 ± 0.02 0.94 ± 0.02 0.92 ± 0.05 1.35 ± 0.02 0.79 ± 0.04 1.37 ± 0.03 0.76 ± 0.04 
C18:3n-6 0.15 ± 0.00 1.04 ± 0.00 0.11 ± 0.00 0.13 ± 0.00 0.20 ± 0.00 0.24 ± 0.00 0.02 ± 0.00 0.48 ± 0.00 0.02 ± 0.00 
C20:0 0.15 ± 0.00 0.12 ± 0.00 0.30 ± 0.00 nd nd 0.02 ± 0.00 nd 0.02 ± 0.00 nd 
C18.3n-3 0.15 ± 0.00 0.06 ± 0.00 0.41 ± 0.00 0.49 ± 0.01 0.52 ± 0.00 0.39 ± 0.00 0.45 ± 0.02 0.56 ± 0.01 0.54 ± 0.01 
C18:4n-3 nd 0.75 ± 0.01 0.78 ± 0.01 1.61 ± 0.04 2.00 ± 0.02 1.41 ± 0.07 1.98 ± 0.06 1.73 ± 0.09 1.78 ± 0.11 
C20:3n-6 1.01 ± 0.01 1.28 ± 0.04 0.25 ± 0.00 0.69 ± 0.01 0.91 ± 0.01 0.53 ± 0.01 0.73 ± 0.04 0.71 ± 0.04 1.25 ± 0.07 
C22:0 0.14 ± 0.00 0.42 ± 0.00 0.45 ± 0.01 0.47 ± 0.00 0.52 ± 0.00 0.39 ± 0.00 0.39 ± 0.00 0.52 ± 0.00 0.38 ± 0.00 
C20:4n-6 12.9 ± 0.15 9.74 ± 0.08 13.2 ± 0.13 11.8 ± 0.14 10.5 ± 0.21 11.1 ± 0.23 10.9 ± 0.21 11.7 ± 0.11 11.2 ± 0.25 
C22:1n-9 nd 0.12 ± 0.00 0.05 ± 0.00 nd nd 0.16 ± 0.00 0.28 ± 0.00 0.21 ± 0.00 0.29 ± 0.00 
C20:5n-3 0.24 ± 0.00 0.49 ± 0.00 1.07 ± 0.03 0.31 ± 0.02 0.30 ± 0.00 0.28 ± 0.00 0.56 ± 0.04 0.63 ± 0.02 1.03 ± 0.06 
C24:0 1.68 ± 0.01 3.56 ± 0.02 1.45 ± 0.03 2.82 ± 0.12 1.65 ± 0.08 3.35 ± 0.01 2.43 ± 0.02 3.34 ± 0.08 2.88 ± 0.07 
C24:1 nd 1.46 ± 0.01 0.35 ± 0.00 0.59 ± 0.01 0.96 ± 0.04 0.66 ± 0.07 0.61 ± 0.01 0.73 ± 0.01 1.64 ± 0.03 
C22:5n-3 0.23 ± 0.00 0.25 ± 0.00 0.23 ± 0.00 0.32 ± 0.01 0.25 ± 0.01 0.30 ± 0.01 0.21 ± 0.00 0.18 ± 0.00 0.25 ± 0.00 
C22:6n-3 6.05 ± 0.05 5.10 ± 0.07 6.55 ± 0.03 13.4 ± 0.21 13.9 ± 0.23 12.9 ± 0.28 13.1 ± 0.21 12.3 ± 0.18 12.9 ± 0.23 
∑ SFA§ 45.3 ± 0.22 54.0 ± 0.18 52.3 ± 0.21 45.0 ± 0.45 29.6 ± 0.51 46.8 ± 0.28 45.7 ± 0.58 45.5 ± 0.45 46.4 ± 0.62 
∑ MUFA# 24.0 ± 0.04 25.7 ± 0.09 23.5 ± 0.03 25.1 ± 0.25 17.0 ± 0.24 24.6 ± 0.52 25.3 ± 0.32 24.9 ± 0.29 24.8 ± 0.35 
∑ PUFA$ 30.7 ± 0.19 20.1 ± 0.10 24.1 ± 0.21 29.9 ± 0.17 11.6 ± 0.23 28.6 ± 0.29 28.7 ± 0.24 29.6 ± 0.18 29.7 ± 0.32 
n-3/n-6 0.36 0.49 0.6 1.21 1.36 1.16 1.31 1.08 1.25 
AA/LA 1.52 6.86 8.63 12.5 11.4 8.25 13.8 8.5 14.7 
AA/DGLA 12.77 7.61 52.8 17.0 11.5 21.0 14.9 16.4 8.9 
EPA/AA 0.13 0.05 0.08 0.04 0.029 0.03 0.05 0.05 0.09 
DHA/EPA 3.60 10.41 6.12 27.43 46.5 46.32 23.34 19.52 12.55 
PI* 123.19 94.02 119.78 170 169.8 161.7 164.5 162.3 167.9 
    ** Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
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Table 9: Fatty acids compositions (%) of liver phospholipids after 4 and 8 weeks* 
 
% DHA 1% DHA 2 % DHA 3% DHA 
Weeks 4 8 4 8 4 8 
C14:0 1.51 ± 0.02 1.53 ± 0.12 1.22 ± 0.10 1.26 ± 0.02 0.58 ± 0.03 0.68 ± 0.02 
C16:0 34.0 ± 0.23 34.0 ± 0.49 33.3 ± 0.32 33.1 ± 0.35 32.2 ± 0.39 32.1 ± 0.65 
C16:1n-7 1.52 ± 0.11 1.79 ± 0.12 1.63 ± 0.11 1.65 ± 0.14 0.88 ± 0.08 0.97 ± 0.08 
C18:0 24.1 ± 0.24 25.6 ± 0.35 24.6 ± 0.32 25.7 ± 0.28 25.2 ± 0.31 25.7 ± 0.24 
C18:1n-9 13.2 ± 0.15 13.3 ± 0.12 13.7 ± 0.15 12.7 ± 0.18 11.3 ± 0.12 11.1 ± 0.21 
C18:1n-7 2.75 ± 0.12 2.93 ± 0.09 2.90 ± 0.05 3.94 ± 0.06 1.68 ± 0.08 1.72 ± 0.09 
C18:2n-6 5.96 ± 0.54 5.13 ± 0.32 6.90 ± 0.35 6.94 ± 0.27 11.2 ± 0.35 12.3 ± 0.32 
C18:3n-6 0.96 ± 0.15 0.60 ± 0.11 0.58 ± 0.02 0.51 ± 0.00 0.26 ± 0.00 0.21 ± 0.11 
C20:0 0.18 ± 0.00 0.16 ± 0.00 nd nd nd nd 
C18.3n-3 1.89 ± 0.12 0.62 ± 0.08 1.90 ± 0.03 0.92 ± 0.03 0.82 ± 0.11 0.45 ± 0.12 
C18:4n-3 0.49 ± 0.12 0.33 ± 0.00 0.42 ± 0.02 0.26 ± 0.02 1.11 ± 0.01 0.80 ± 0.13 
C20:1n-9 0.62 ± 0.11 0.55 ± 0.00 0.43 ± 0.03 0.46 ± 0.01 1.10 ± 0.09 0.96 ± 0.21 
C22:0 0.58 ± 0.02 0.65 ± 0.01 0.88 ± 0.12 0.72 ± 0.09 0.50 ± 0.02 0.40 ± 0.04 
C20:4n-6 7.02 ± 0.28 4.27 ± 0.24 6.10 ± 0.15 2.97 ± 0.21 5.81 ± 0.56 2.94 ± 0.19 
C22:1n-9 0.35 ± 0.02 0.10 ± 0.00 0.50 ± 0.03 0.55 ± 0.01 0.12 ± 0.00 0.40 ± 0.03 
C20:5n-3 0.71 ± 0.04 0.50 ± 0.02 0.73 ± 0.11 0.15 ± 0.00 1.76 ± 0.05 1.02 ± 0.04 
C24:0 1.23 ± 0.13 1.13 ± 0.01 1.03 ± 0.03 1.14 ± 0.03 0.66 ± 0.03 0.68 ± 0.08 
C22:5n- 0.22 ± 0.00 0.18 ± 0.00 0.21 ± 0.01 0.06 ± 0.00 1.67 ± 0.04 0.39 ± 0.03 
C22:6n-3 2.62 ± 0.14 6.54 ± 0.31 2.69 ± 0.21 6.95 ± 0.32 2.89 ± 0.21 6.98 ± 0.54 
SFA 61.6 ± 0.45 63.1 ± 0.65 61.0 ± 0.65 61.9 ± 0.63 59.1 ± 0.69 59.6 ± 0.75 
MUFA 17.8 ± 0.32 18.1 ± 0.21 18.7 ± 0.21 18.9 ± 0.32 13.9 ± 0.25 14.2 ± 0.27 
PUFA 20.5 ± 0.65 18.7 ± 0.60 19.9 ± 0.52 19.2 ± 0.71 26.6 ± 0.87 26.1 ± 0.75 
n-3/n-6 0.41 0.77 0.42 0.77 0.45 0.59 
AA/LA 1.18 0.83 0.88 0.43 0.52 0.24 
AA/DGLA 11.32 7.76 14.19 6.46 5.28 3.06 
EPA/AA 0.10 0.12 0.12 0.05 0.30 0.35 
DHA/EPA 3.69 13.08 3.68 46.33 1.64 6.84 
PI 69.93 83.92 66.43 80.97 87.29 95.15 
* Each parameter given is the mean from three rat’s ± SD. For abbreviations see table 3. 
               
 
TABLES AND FIGURES 
 79  
  Table 10: Fatty acids composition (%) of liver phospholipids after 4 and 8 weeks* 
% GLA 1% GLA 3% GLA 5% GLA 
Weeks 4 8 4 8 4 8 
C14:0 1.56 ± 0.08 1.62 ± 0.04 0.49 ± 0.01 0.82 ± 0.03 0.57 ± 0.01 0.64 ± 0.03 
C16:0 22.4 ± 0.17 26.4 ± 0.21 26.8 ± 0.29 28.0 ± 0.32 24.4 ± 0.38 27.7 ± 0.39 
C16:1n-7 1.93 ± 0.11 1.66 ± 0.03 1.25 ± 0.03 2.08 ± 0.08 1.23 ± 0.04 0.99 ± 0.04 
C18:0 24.0 ± 0.32 25.6 ± 0.21 23.0 ± 0.17 25.2 ± 0.28 24.9 ± 0.28 25.8 ± 0.38 
C18:1n-9+n-7 15.1 ± 0.27 16.9 ± 0.24 11.2 ± 0.21 13.3 ± 0.15 12.3 ± 0.21 13.2 ± 0.28 
C18:2n-6 6.15 ± 0.12 5.05 ± 0.11 7.92 ± 0.15 6.59 ±  0.21 8.74 ± 0.15 7.28 ± 0.19 
C18:3n-6 0.99 ± 0.05 0.64 ± 0.07 0.58 ± 0.02 0.27 ± 0.00 0.85 ± 0.11 0.19 ± 0.00 
C20:0 0.68 ± 0.01 0.16 ± 0.00 0.26 ± 0.00 0.75 ± 0.01 0.16 ± 0.00 0.19 ± 0.00 
C18.3n-3 1.10 ± 0.06 0.65 ± 0.05 0.96 ± 0.04 0.99 ± 0.05 0.82 ± 0.08 0.82 ± 0.05 
C18:4n-3 0.51 ± 0.01 0.35 ± 0.03 0.30 ± 0.00 0.30 ± 0.00 0.30 ± 0.00 0.42 ± 0.04 
C20:3n-6 0.65 ± 0.02 0.58 ± 0.01 0.76 ± 0.06 0.65 ± 0.01 0.89 ± 0.03 1.54 ± 0.07 
C22:0 1.48 ± 0.06 1.41 ± 0.07 0.55 ± 0.01 1.59 ± 0.09 0.39 ± 0.01 0.81 ± 0.06 
C20:4n-6 12.1 ± 0.34 10.5 ± 0.11 16.8 ± 0.19 12.4 ± 0.32 16.9 ± 0.21 13.9 ± 0.18 
C22:1n-9 0.37 ± 0.00 0.10 ± 0.00 nd nd nd nd 
C20:5n-3 0.74 ± 0.07 0.53 ± 0.02 0.99 ± 0.08 0.62 ± 0.01 0.88 ± 0.08 0.19 ± 0.00 
C24:0 0.66 ± 0.03 0.93 ± 0.07 0.74 ± 0.04 0.63 ± 0.03 0.68 ± 0.04 0.68 ± 0.07 
C22:5n-3 0.98 ± 0.03 0.23 ± 0.00 0.82 ± 0.05 0.59 ± 0.02 0.63 ± 0.02 0.62 ± 0.01 
C22:6n-3 8.51 ± 0.11 6.25 ± 0.21 6.53 ± 0.09 5.35 ± 0.15 6.02 ± 0.21 4.99 ± 0.11 
SFA 50.9 ± 0.55 56.2 ± 0.51 51.9 ± 0.46 57.0 ± 0.68 51.1 ± 0.67 55.9 ± 0.45 
MUFA 17.4 ± 0.37 18.7 ± 0.26 12.4 ± 0.23 15.3 ± 0.23 13.5 ± 0.25 14.2 ± 0.32 
PUFA 11.8 ± 0.27 8.01 ± 0.32 9.61 ± 0.25 7.85 ± 0.24 8.65 ± 0.32 7.03 ± 0.22 
n-3/n-6 0.60 0.48 0.37 0.39 0.32 0.31 
AA/LA 1.97 2.08 2.12 1.88 1.93 1.91 
AA/DGLA 18.62 18.10 22.11 19.08 18.99 9.03 
EPA/AA 0.06 0.05 0.06 0.05 0.05 0.01 
DHA/EPA 11.50 11.79 6.60 8.63 6.84 26.26 
PI 140.91 107.22 144.33 111.65 140.21 114.79 
* Each parameter given is the mean from three rat’s ± SD. For abbreviations see Table 3. 
 
 
 
 
 
 
TABLES AND FIGURES 
 80  
Table 11: Fatty acids compositions (%) of brain phospholipids after 4 and 8 weeks* 
% DHA 1% DHA 2%  DHA 3% DHA 
Weeks 4 8 4 8 4 8 
C14:0 0.93 ± 0.02 1.04 ± 0.06 0.62 ± 0.03 0.64 ± 0.05 0.67 ± 0.04 0.62 ± 0.09 
C16:0 37.5 ± 0.25 37.6 ± 0.32 37.0 ± 0.28 37.2 ± 0.35 33.7 ± 0.39 33.8 ± 0.21 
C16:1n-7 1.20 ± 0.02 1.44 ± 0.05 1.09 ± 0.06 1.26 ± 0.02 0.82 ± 0.02 1.37 ± 0.05 
C18:0 17.3 ± 0.15 17.6 ± 0.21 17.2 ± 0.18 17.3 ± 0.16 18.3 ± 0.21 18.6 ± 0.24 
C18:1n-9 19.5 ± 0.18 19.8 ± 0.23 20.4 ± 0.31 20.6 ± 0.24 20.4 ± 0.25 20.9 ± 0.21 
C18:1n-7 5.47 ± 0.06 5.77 ± 0.11 4.72 ± 0.08 4.83 ± 0.09 5.60 ± 0.14 4.78 ± 0.11 
C18:2n-6 0.76 ± 0.02 0.72 ± 0.05 0.95 ± 0.05 1.56 ± 0.02 0.95 ± 0.07 2.16 ± 0.09 
C18:3n-6 0.44 ± 0.01 0.57 ± 0.02 0.30 ± 0.00 0.68 ± 0.03 0.28 ± 0.02 0.79 ± 0.07 
C20:0 nd nd 0.36 ± 0.00 0.41 ± 0.08 0.43 ± 0.04 0.41 ± 0.04 
C18.3n-3 1.36 ± 0.06 0.84 ± 0.09 1.74 ± 0.02 0.31 ± 0.00 1.88 ± 0.06 0.91 ± 0.02 
C18:4n-3 2.07 ± 0.08 1.53 ± 0.07 1.72 ± 0.03 1.42 ± 0.05 2.67 ± 0.04 2.13 ± 0.11 
C20:3n-6 0.20 ± 0.00 0.24 ± 0.00 0.33 ± 0.05 0.55 ± 0.02 0.36 ± 0.01 0.54 ± 0.03 
C22:0 0.41 ± 0.04 0.18 ± 0.05 0.41 ± 0.02 0.26 ± 0.01 0.60 ± 0.01 0.28 ± 0.04 
C20:4n-6 6.28 ± 0.19 3.92 ± 0.21 5.90 ± 0.09 3.79 ± 0.11 5.82 ± 0.18 3.70 ± 0.10 
C22:1n-9 0.48 ± 0.01 0.24 ± 0.02 0.13 ± 0.00 0.43 ± 0.03 0.08 ± 0.00 0.06 ± 0.00 
C20:5n-3 0.40 ± 0.02 0.22 ± 0.01 0.56 ± 0.02 0.22 ± 0.00 0.58 ± 0.00 0.28 ± 0.00 
C24:0 1.40 ± 0.04 1.41 ± 0.02 1.68 ± 0.11 1.72 ± 0.12 1.61 ± 0.08 1.56 ± 0.09 
C22:5n- 0.15 ± 0.02 0.10 ± 0.00 0.32 ± 0.00 0.22 ± 0.03 0.21 ± 0.00 0.12 ± 0.00 
C22:6n-3 3.78 ± 0.14 6.76 ± 0.28 3.98 ± 0.19 6.91 ± 0.21 4.78 ± 0.32 6.81 ± 0.21 
SFA 57.5 ± 0.37 57.8 ± 0.48 57.3 ± 0.41 57.5 ± 0.42 55.3 ± 0.58 55.3 ± 0.41 
MUFA 26.7 ± 0.18 27.3 ± 0.35 26.4 ± 0.34 26.8 ± 0.28 26.9 ± 0.38 27.1 ± 0.28 
PUFA 15.4 ± 0.30 14.9 ± 0.41 15.8 ± 0.28 15.7 ± 0.25 17.5 ± 0.45 17.4 ± 0.32 
n-3/n-6 1.01 1.73 1.11 1.38 1.37 1.43 
AA/LA 8.26 5.44 6.21 2.43 6.13 1.71 
AA/DGLA 31.40 16.33 17.88 6.89 16.17 6.85 
EPA/AA 0.06 0.06 0.09 0.06 0.10 0.08 
DHA/EPA 9.45 30.73 7.11 31.41 8.24 24.32 
PI 72.37 82.50 73.95 84.07 83.60 87.52 
* Each parameter given is the mean from three rat’s ± SD. For abbreviations see Table 3. 
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   Table 12: Fatty acids composition (%) of Brain phospholipids after 4 and 8 weeks* 
% GLA 1% GLA 3% GLA 5% GLA 
Weeks 4 8 4 8 4 8 
C14:0 0.95 ± 0.02 1.07 ± 0.05 0.71 ± 0.02 0.98 ± 0.08 0.45 ± 0.02 0.54 ± 0.02 
C16:0 30.4 ± 0.23 32.5 ± 0.32 32.5 ± 0.21 32.9 ± 0.35 30.9 ± 0.32 32.0 ± 0.38 
C16:1n-7 1.47 ± 0.02 1.23 ± 0.04 1.28 ± 0.04 1.15 ± 0.09 0.59 ± 0.00 0.53 ± 0.02 
C18:0 18.8 ± 0.25 19.1 ± 0.19 18.2 ± 0.21 17.5 ± 0.11 20.1 ± 0.09 22.5 ± 0.21 
C18:1n-9+n-7 25.2 ± 0.32 25.3 ± 0.21 24.0 ± 0.30 24.0 ± 0.24 24.1 ± 0.12 24.1 ± 0.25 
C18:2n-6 0.78 ± 0.05 0.73 ± 0.01 2.83 ± 0.11 3.31 ± 0.13 2.55 ± 0.06 0.95 ± 0.01 
C18:3n-6 0.46 ± 0.01 0.59 ± 0.03 0.58 ± 0.07 0.91 ± 0.07 0.48 ± 0.02 0.99 ± 0.01 
C20:0 0.40 ± 0.02 0.62 ± 0.01 0.44 ± 0.05 0.44 ± 0.01 0.57 ± 0.03 0.63 ± 0.02 
C18.3n-3 0.87 ± 0.08 1.39 ± 0.05 1.23 ± 0.04 2.27 ± 0.12 0.59 ± 0.03 0.89 ± 0.01 
C18:4n-3 1.57 ± 0.04 2.11 ± 0.11 1.18 ± 0.03 1.31 ± 0.10 1.70 ± 0.01 2.04 ± 0.03 
C20:3n-6 0.21 ± 0.00 0.25 ± 0.00 0.22 ± 0.00 0.87 ± 0.02 0.48 ± 0.01 0.36 ± 0.01 
C22:0 0.83 ± 0.05 0.95 ± 0.02 0.50 ± 0.01 0.85 ± 0.01 0.57 ± 0.04 0.79 ± 0.01 
C20:4n-6 7.98 ± 0.15 5.64 ± 0.11 8.23 ± 0.21 5.98 ± 0.09 8.45 ± 0.11 6.25 ± 0.11 
C22:1n-9 0.49 ± 0.02 0.27 ± 0.01 0.12 ± 0.00 0.23 ± 0.00 0.50 ± 0.02 0.33 ± 0.00 
C20:5n-3 0.41 ± 0.00 0.43 ± 0.02 0.23 ± 0.00 0.47 ± 0.01 0.60 ± 0.01 0.79 ± 0.01 
C24:0 1.41 ± 0.11 1.44 ± 0.03 1.32 ± 0.01 1.59 ± 0.18 1.57 ± 0.11 1.61 ± 0.03 
C22:5n-3 0.10 ± 0.00 0.16 ± 0.00 0.11 ± 0.00 0.14 ± 0.00 0.19 ± 0.00 0.13 ± 0.00 
C22:6n-3 7.62 ± 0.15 6.18 ± 0.11 6.36 ± 0.21 5.12 ± 0.14 5.57 ± 0.24 4.61 ± 0.08 
SFA 52.8 ± 0.48 55.7 ± 0.54 53.6 ± 0.47 54.2 ± 0.49 54.2 ± 0.44 58.1 ± 0.60 
MUFA 27.2 ± 0.33 26.8 ± 0.25 25.4 ± 0.33 25.4 ± 0.32 25.1 ± 0.13 24.9 ± 0.26 
PUFA 20.0 ± 0.48 17.5 ± 0.35 20.9 ± 0.54 20.4 ± 0.61 20.6 ± 0.41 17.0 ± 0.25 
n-3/n-6 1.12 1.42 0.77 0.84 0.72 0.99 
AA/LA 10.2 7.73 2.91 1.81 3.31 6.58 
AA/DGLA 38.00 22.56 37.41 6.87 17.60 17.36 
EPA/AA 0.05 0.08 0.03 0.08 0.07 0.13 
DHA/EPA 18.59 14.37 27.65 10.89 9.28 5.84 
PI 106.76 89.84 98.09 85.82 96.18 81.61 
 * Each parameter given is the mean from three rat’s ± SD. For abbreviations see Table 3. 
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Table 13: Concentration of alpha tocopherols at all time points in 
tissues and plasma in omega 3 group and omega 6 groups. 
 Groups 
    Tissues 
Weeks 
 
Formulas 
2 4 6 8 
1 DHA 78.62 48.57 18.57 9.88 
2 DHA 69.21 41.46 13.58 8.18 Brain 
µg /total brain  
 
3 DHA  55.34 39.04 8.44 6.11 
1 DHA 89.97 80.29 77.9 24.68 
2 DHA 77.26 65.74 57.26 18.99 Liver 
µg/total liver 
 
3 DHA  65.67 41.61 19.57 15.53 
1 DHA 5.34 11.1 4.30 5.66 
2 DHA 7.48 8.52 5.70 5.74 
   Omega-3  
     group 
 
 
 
 
 
 
Plasma 
mg/ L Plasma 
 
3 DHA  8.90 8.62 4.78 3.00 
  
   
     
1 gamma 72.51 47.57 18.97 7.88 
3 gamma 65.91 45.46 16.24 6.94 Brain  
µg/total brain 
 
5 gamma 53.12 32.54 16.82 6.84 
1 gamma 80.29 77.9 24.68 21.13 
3 gamma 77.15 68.41 21.13 16.6 Liver 
µg/total liver 
 
5 gamma 62.52 58.77 18.04 12.5 
1 gamma 3.10 5.34 4.30 5.66 
3 gamma 1.98 8.82 6.58 5.68 
 
 
Omega-6 
group 
 
 
 
 
 
 
Plasma 
mg/L plasma 
 5 gamma 1.76 4.08 2.50 2.48 
 
 
Table 14: Percent of fatty acids classification of oils and extracted oils (EO) 
 
  Oils EO 
           Oils component  
Oils fractions 1%GLA 3%GLA 3%DHA 1%GLA 3%GLA 3%DHA 
NL  90.1 91.0 93.2 81.1 80.2 79.9 
GL  6.9 6.7 4.9 8.1 8.6 9.5 
PL  2.9 1.5 1.8 10.2 11.0 10.3 
S/ P* 0.652 0.523 0.498 0.751 0.526 0.485 
Total phenolic** 4 5 10 5 7 11 
* S/ P ratio saturated to unsaturated fatty acids in phospholipids. 
**Total phenolic excess as caffeic acid (ppm). 
 
 
TABLES AND FIGURES 
 83  
     Table 15: Inhibition of formation of propanal and hexanal by tocopherol in bulk  
                  oils and extracted oils (EO) and their fractions (Percent Mean Inhibition  
                  SD)a 
 Propanal Hexanal 
sample day 4 day 6 day 4 day 6 
control oil 0.0 0.0 0.0 0.0 
 1% GLA 33.5 41.7 62.5 66.7 
 3% GLA 3.1 18.8 41.7 33.3 
 3% DHA -2.6 6.1 45.8 66.7 
     
EO control 0.0 0,0 0.0 ND 
EO 1%GLA 22.7 79,9 44.4 ND 
EO 3% GLA -0.3 75,8 22.2 ND 
EO 3% DHA -30.9 63,8 33.3 ND 
NL     
control oil 0.0 0.0 0.0 0.0 
 1% GLA 37.2 50.8 91.1 92.7 
 3% GLA -1.0 31.8 73.2 78.2 
 3% DHA 12.6 20.5 ND ND 
     
EO control 0.0 0.0 0.0 0.0 
EO 1% GLA 6.2 60.1 16.3 98.1 
EO 3% GLA -10.4 54.3 -44.9 96.3 
EO 3% DHA -71.3 25.9 -4.1 96.3 
Polar lipid day 4 day 8 day 4 day 8 
control oil 0.0 0.0 0.0 0.0 
 1% GLA 59.8 75,4 38.7 90.1 
 3% GLA 45.9 74,5 -79.9 76.7 
 3% DHA 33.5 51,7 96.2 93.5 
     
EO control 0,0 0,0 0,0 0,0 
EO 1%GLA 47,8 70.8 40.7 77.0 
EO 3% GLA 43,3 60.4 -75.2 41.0 
EO 3% DHA 0,1 51.9 97.4 90.1 
 
      a % inhibition = (C-S)/S*100; C=hexanal or propanal formation in control and S =   
     hexanal or propanal formation in sample. Negative represent prooxidant activity;  
     SD standard deviations;  the initial inhibition of hexanal formation was not           
     calculated because hexanal formation did not increase until after 4 days of   
     oxidation.  
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         1 
  
Figure 3a: Tocopherols Standard, 1: α-Tocopherol, 2: β-Tocopherol, 3: Ŗ-
Tocopherol, 4: ∆-Tocopherol detection with NP-HPLC at 295 nm and used 
isooctane: acetylacetate 96:4 (v/v) as a mobile phase. 
 
                                                                        
Figure 3b: Chosen volatile aldehyde standards by GC-HS.Peaks numbered 
correspond to 1, propanal; 2, penatanl; 3, hexanal; 4, octanal and 5, 
nonanal 
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Figure 4: Changes in rat weight gains during 56 days. 
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Figure 5: Changes in the fatty acids in plasma 
phospholipids after 4 weeks
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Figure 6: Changes in the fatty acids in plasma 
phospholipids after 8 weeks
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Figure 8a:  Effect of brain total lipid on DPPH
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  Figure 8b: Effect of brain total lipid on DPPH
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Figure 9: Changes in peroxide levels of bulk (A) and extracted (B) oils during 
storage test 
 
TABLES AND FIGURES 
 89  
 
 
A
0
5
10
15
20
25
0 48 96 144 192 240 288
Hours
 Control oil
 1% GLA
 3% GLA
 3% DHA
 
B
0
30
60
90
120
0 48 96 144 192 240 288
Hours
 Control oil
 EO 1%GLA
 EO 3%GLA
 EO 3%DHA
 
Figure 10: Changes in p-anisidine values of bulk (A) and extracted (B) oils 
during storage test 
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  (I) Neutral lipids  
                         
  (II) Glycolipids  
                       
   (III) Phosopholipids  
                            
Figure 11: Ultraviolet scans between 220 and 320 nm after 12 days storage at 60 
ºC, (A), Oils: 1, 1%GLA; 2, 3%GLA; 3, 3%DHA; (B), EO: 4, EO 1%GLA; 5, EO 
3%GLA; 6, EO 3%DHA. 
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Figure 12: Absorpitivity at 233 nm of oils (A), Neutral lipids (B), Glycolipids (C) and phospholipds (D) during storage 
period at 60 ºC. Error bars show the variations of the three determinations in terms of standard deviation. 
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Figure 13: Absorpitivity at 270 nm of oils (A), Neutral lipids (B), Glycolipids (C) and phospholipds (D) during storage 
period at 60 ºC. Error bars show the variations of the three determinations in terms of standard deviation. 
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Figure 14: Absorpitivity at 233 nm of extracted oils (EO); (A), Neutral lipids (B), Glycolipids (C) and phospholipds (D) during 
storage period at 60 ºC. Error bars shows the variations of the three determinations in terms of standard deviation. 
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Figure 15: Absorpitivity at 270 nm of extracted oils (EO); (A), Neutral lipids (B), Glycolipids (C) and phospholipds (D) 
during storage period at 60 ºC. EO, extracted oil from formulas .Error bars shows the variations of the three 
determinations in terms of standard deviation. 
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Figure 16a: Propanal content in (A), Oils; (B), Neutral lipids and polar lipids (C)
during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16b: Propanal content in (A), Extracted oils; (B), Neutral lipids and polar 
lipids (C) during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16c: Hexanal content in (A), Oils; (B), Neutral lipids and polar lipids (C)
during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16d: Hexanal content in (A), Extracted oils; (B), Neutral lipids and polar 
lipids (C) during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16e: Pentanal content in (A), Oils; (B), Neutral lipids and polar lipids (C)
during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16f: Hexanal content in (A), Extracted oils; (B), Neutral lipids and polar 
lipids (C) during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16g: Pentanal content in (A), Oils; (B), Neutral lipids and polar lipids (C)
during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 16h: Nonanal content in (A), Extracted oils; (B), Neutral lipids and polar 
lipids (C) during storage period at 60 ºC. Error bars show the variations of the three 
determinations in terms of standard deviation. 
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Figure 17: Malondialdehyde contents in (A) bulk and (B) extracted oils 
during storage period. 
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